Articles published in Inflamm Bowel Dis\nRetrieve available abstracts of 611 articles:\nLEITE-GOMES E, Dias AM, Azevedo CM, Santos-Pereira B, et al\nBringing to Light the Risk of Colorectal Cancer in Inflammatory Bowel Disease: Mucosal Glycosylation as a Key Player.\nInflamm Bowel Dis. 2021 Nov 29. pii: 6446097. doi: 10.1093.\nSUN Y, Geng J, Chen X, Chen H, et al\nAssociation Between Inflammatory Bowel Disease and Dementia: A Longitudinal Cohort Study.\nInflamm Bowel Dis. 2021 Nov 29. pii: 6445975. doi: 10.1093.\nCERNA K, Duricova D, Lukas M, Machkova N, et al\nAnti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.\nInflamm Bowel Dis. 2021 Nov 29. pii: 6445976. doi: 10.1093.\nZHANG W, Scalori A, Fuh F, McBride J, et al\nPharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease: Results from a Phase 1 Randomized Trial.\nInflamm Bowel Dis. 2021 Nov 29. pii: 6446094. doi: 10.1093.\nBIRDA CL, Agarwal A, Goyal A\nA Rare Case of Hearing Loss in a Patient With Ulcerative Colitis.\nInflamm Bowel Dis. 2021 Nov 24. pii: 6438178. doi: 10.1093.\nDESALERMOS A, Pimienta M, Kalligeros M, Shehadeh F, et al\nSafety of Immunizations for the Adult Patient With Inflammatory Bowel Disease-A Systematic Review and Meta-analysis.\nInflamm Bowel Dis. 2021 Nov 24. pii: 6438176. doi: 10.1093.\nKJELDSEN S, Nielsen J, Mertz Norgard B, Kjeldsen J, et al\nMesalazine in Inflammatory Bowel Disease and COVID-19: Hospitalization and Adverse In-Hospital Outcomes Based on Nationwide Data.\nInflamm Bowel Dis. 2021 Nov 24. pii: 6438420. doi: 10.1093.\nWESTBERG K, Olen O, Soderling J, Bengtsson J, et al\nInflamm Bowel Dis. 2021 Nov 18. pii: 6430979. doi: 10.1093.\nSACHAN A, Singh AK\nReply to Response to "Strongyloides stercoralis in Acute Severe Ulcerative Colitis-A Triggering Nuisance or an Opportunistic Bystander?" by Hokama et al.\nInflamm Bowel Dis. 2021 Nov 15. pii: 6428578. doi: 10.1093.\nPAPALIA I, Tjandra D, Quah S, Tan C, et al\nColon Capsule Endoscopy in the Assessment of Mucosal Healing in Crohn's Disease.\nInflamm Bowel Dis. 2021;27.\nHANZEL J, Dreesen E, Vermeire S, Lowenberg M, et al\nCorrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study.\nInflamm Bowel Dis. 2021 Nov 12. pii: 6426108. doi: 10.1093.\nHOKAMA A, Fujita J\nResponse to "Strongyloides stercoralis in Acute Severe Ulcerative Colitis-A Triggering Nuisance or an Opportunistic Bystander?"\nInflamm Bowel Dis. 2021 Nov 12. pii: 6426022. doi: 10.1093.\nLUTZ MK, Matthews LA, Tuan WJ, Caldera F, et al\nDid You Get My Message? Trends and Predictors of Inflammatory Bowel Disease Patient-to-Provider Electronic Messaging.\nInflamm Bowel Dis. 2021 Nov 10. pii: 6425060. doi: 10.1093.\nJAGT JZ, Struys EA, Ayada I, Bakkali A, et al\nFecal Amino Acid Analysis in Newly Diagnosed Pediatric Inflammatory Bowel Disease: A Multicenter Case-Control Study.\nInflamm Bowel Dis. 2021 Nov 10. pii: 6425057. doi: 10.1093.\nJENA A, Singh AK, Siddharda BV, Panda P, et al\nMesalamine-Induced Perimyocarditis: Rare Adverse Event in a Patient With Acute Severe Ulcerative Colitis.\nInflamm Bowel Dis. 2021 Nov 9. pii: 6425058. doi: 10.1093.\nZHANG S, Chen F, Wu J, Liu C, et al\nInflamm Bowel Dis. 2021 Nov 3. pii: 6420319. doi: 10.1093.\nTRIPATHI K, Godoy Brewer G, Thu Nguyen M, Singh Y, et al\nCOVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.\nInflamm Bowel Dis. 2021 Oct 27. pii: 6412576. doi: 10.1093.\nDAI C, Huang YH, Jiang M\nSuccessful Treatment of Ulcerative Colitis, Rectovaginal Fistula, and Skin Erythema Nodule With Adalimumab.\nInflamm Bowel Dis. 2021 Oct 27. pii: 6412248. doi: 10.1093.\nKING D, Chandan JS, Thomas T, Nirantharakumar K, et al\nThe Risk of Later Diagnosis of Inflammatory Bowel Disease in Patients With Dermatological Disorders Associated With Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2021;27:1731-1739.\nSPENCER EA, Klang E, Dolinger M, Pittman N, et al\nInflamm Bowel Dis. 2021;27:1862-1864.\nCRISPINO F, Brinch D, Carrozza L, Cappello M, et al\nAcceptance of SARS-CoV-2 Vaccination Among a Cohort of IBD Patients From Southern Italy: A Cross-Sectional Survey.\nInflamm Bowel Dis. 2021;27:e134-e135.\nDALAL RS, Allegretti JR\nFecal Microbiota Transplantation for Chronic Pouchitis: Promising Novel Therapeutic or Lost Cause?\nInflamm Bowel Dis. 2021;27:1873-1875.\nCALDERA F, Balzora S, Hayney MS, Farraye FA, et al\nInflamm Bowel Dis. 2021;27:1703-1705.\nREENAERS C, de Roover A, Kohnen L, Nachury M, et al\nInflamm Bowel Dis. 2021 Oct 12. pii: 6391132. doi: 10.1093.\nANNE SHAFER L, Shaffer S, Witt J, Nugent Z, et al\nIBD Disability Index Is Associated With Both Direct and Indirect Costs of Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2021 Oct 12. pii: 6390721. doi: 10.1093.\nYU N, Basnayake C, Connell W, Ding NS, et al\nInterventions to Improve Adherence to Preventive Care in Inflammatory Bowel Disease: A Systematic Review.\nInflamm Bowel Dis. 2021 Oct 7. pii: 6383125. doi: 10.1093.\nHOWALDT S, Domenech E, Martinez N, Schmidt C, et al\nCorrigendum to: Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial.\nInflamm Bowel Dis. 2021 Oct 6. pii: 6382159. doi: 10.1093.\nRAMAN M, Rajagopalan V, Kaur S, Reimer RA, et al\nPhysical Activity in Patients With Inflammatory Bowel Disease: A Narrative Review.\nInflamm Bowel Dis. 2021 Oct 4. pii: 6380888. doi: 10.1093.\nLEE KE, Lim F, Colombel JF, Hur C, et al\nCost-effectiveness of Venous Thromboembolism Prophylaxis After Hospitalization in Patients With Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2021 Sep 30. pii: 6378418. doi: 10.1093.\nGU X, Ke X, Shen M, Zhang M, et al\nInflamm Bowel Dis. 2021 Sep 30. pii: 6378417. doi: 10.1093.\nMICHEL HK, Boyle B, David J, Donegan A, et al\nInflamm Bowel Dis. 2021 Sep 25. pii: 6375326. doi: 10.1093.\nBOOTH A, Ford W, Brennan E, Magwood G, et al\nInflamm Bowel Dis. 2021 Sep 23. pii: 6374390. doi: 10.1093.\nMACISAAC MB, Julsgaard M, Flanagan E, Rowe S, et al\nAnti-TNFalpha Induction Therapy for Patients With Active Inflammatory Bowel Disease During Pregnancy: A Case Series.\nInflamm Bowel Dis. 2021 Sep 18. pii: 6372251. doi: 10.1093.\n"The Tough Get Going": Understanding the Role of Resilience and a Multidimensional Conceptualization of Mental Health Among Patients With Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2021 Sep 17. pii: 6371841. doi: 10.1093.\nDAILEY J, Kozhaya L, Dogan M, Hopkins D, et al\nInflamm Bowel Dis. 2021 Sep 16. pii: 6371006. doi: 10.1093.\nExpanding Contributions of Monogenic Very Early Onset Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2021 Sep 15. pii: 6370827. doi: 10.1093.\nBADER-MEUNIER B, Martins AL, Charbit-Henrion F, Meinzer U, et al\nInflamm Bowel Dis. 2021 Sep 15. pii: 6370829. doi: 10.1093.\nVAHIDNEZHAD H, Youssefian L, Anbardar MH, Zeinali S, et al\nVery-Early-Onset Inflammatory Bowel Disease in a Patient With Junctional Epidermolysis Bullosa With a Homozygous Mutation in the alpha6 Integrin Gene (ITGA6).\nInflamm Bowel Dis. 2021 Sep 15. pii: 6370826. doi: 10.1093.\nMISHRA S, Kumar Singh A, Kopp C, Jena A, et al\nTubercular Pleural Effusion in a Patient of Ulcerative Colitis Treated With Tofacitinib.\nInflamm Bowel Dis. 2021 Sep 15. pii: 6370835. doi: 10.1093.\nDE VOOGD F, Joshi H, Van Wassenaer E, Bots S, et al\nIntestinal Ultrasound to Evaluate Treatment Response During Pregnancy in Patients With Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2021 Sep 15. pii: 6370832. doi: 10.1093.\nWU N, Li H, Zhang J, Huang W, et al\nHerpes Zoster in a Patient With Ulcerative Colitis After Vedolizumab Initiation-Causal Link or Only Temporal Coincidence?\nInflamm Bowel Dis. 2021 Sep 4. pii: 6364140. doi: 10.1093.\nHERMAN SM, Zaborniak K, Bernstein CN\nInsight into Inflammatory Bowel Disease Pathogenesis: Is the Answer Blowing in the Wind?\nInflamm Bowel Dis. 2021 Sep 2. pii: 6362805. doi: 10.1093.\nBARNES EL, Nowell WB, Venkatachalam S, Dobes A, et al\nRacial and Ethnic Distribution of Inflammatory Bowel Disease in the United States.\nInflamm Bowel Dis. 2021 Sep 2. pii: 6362806. doi: 10.1093.\nPHILIPPOU A, Sehgal P, Ungaro RC, Wang K, et al\nHigh Levels of Psychological Resilience Are Associated With Decreased Anxiety in Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2021 Aug 27. pii: 6358608. doi: 10.1093.\nXERFAN EMS, Andersen ML, Tomimori J, Tufik S, et al\nInflammatory Bowel Disease, Skin, and Sleep: An Overview of This Complex Interaction and Associated Issues.\nInflamm Bowel Dis. 2021 Aug 27. pii: 6358561. doi: 10.1093.\nRAFFALS LE, Saha S, Bewtra M, Norris C, et al\nThe Development and Initial Findings of A Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD).\nInflamm Bowel Dis. 2021 Aug 26. pii: 6358125. doi: 10.1093.\nMATSUNE Y, Yaguchi K, Saito S, Sakakibara H, et al\nSimultaneous Development of Ulcerative Colitis in the Sigmoidocolon Autotransplant Neovagina and the Residual Colorectum.\nInflamm Bowel Dis. 2021 Aug 26. pii: 6358126. doi: 10.1093.\nHASSAN-ZAHRAEE M, Ye Z, Xi L, Baniecki ML, et al\nAntitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis.\nInflamm Bowel Dis. 2021 Aug 24. pii: 6357022. doi: 10.1093.\nMALHI G, Tandon P, Perlmutter JW, Nguyen G, et al\nRisk Factors for Postpartum Disease Activity in Women With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.\nInflamm Bowel Dis. 2021 Aug 24. pii: 6357024. doi: 10.1093.\nXU Y, Tian Y, Li F, Wang Y, et al\nCircular RNA HECTD1 Mitigates Ulcerative Colitis by Promoting Enterocyte Autophagy Via miR-182-5p/HuR Axis.\nInflamm Bowel Dis. 2021 Aug 24. pii: 6357021. doi: 10.1093.\nSABERZADEH-ARDESTANI B, Anushiravani A, Mansour-Ghanaei F, Fakheri H, et al\nInflamm Bowel Dis. 2021 Aug 21. pii: 6356100. doi: 10.1093.\nYANG Q, Chen L, Feng L, Liu C, et al\nSuccess of Cyclosporin and Tofacitinib Combination Therapy in a Patient With Severe Steroid-refractory Ulcerative Colitis.\nInflamm Bowel Dis. 2021 Aug 16. pii: 6352953. doi: 10.1093.\nDEL SORDO R, Lupinacci G, Tanzi G, Bassotti G, et al\nImatinib and Dasatinib-induced Ulcerative Colitis: Case Report.\nInflamm Bowel Dis. 2021 Aug 10. pii: 6347487. doi: 10.1093.\nUNGARO RC, Agrawal M, Brenner EJ, Zhang X, et al\nInflamm Bowel Dis. 2021 Jul 28. pii: 6329562. doi: 10.1093.\nFALSEY A, Jo D, Sirak H, Moya D, et al\nCorticosteroids Can Be Used to Decrease Antidrug Antibodies in Pediatric Patients With Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2021 Jul 28. pii: 6329558. doi: 10.1093.\nAXELRAD JE, Faye A, Slaughter JC, Harpaz N, et al\nColorectal Strictures in Patients With Inflammatory Bowel Disease Do Not Independently Predict Colorectal Neoplasia.\nInflamm Bowel Dis. 2021 Jul 28. pii: 6329560. doi: 10.1093.\nMARKOVIC S, Ivanovski TK, Zogovic B, Kalaba A, et al\nThe Effect of COVID-19 Resurgence on Morbidity and Mortality in Patients With IBD on Biologic Therapy.\nInflamm Bowel Dis. 2021;27:e90.\nWINTER MW, Levy LC\nMaybe Age Isn't Just a Number: Elderly-onset IBD Is a Demographic Deserving of Specific Considerations.\nInflamm Bowel Dis. 2021;27:1363-1364.\nCHIBA M, Ishii H, Sageshima M, Iwabuchi A, et al\nAppendiceal Orifice Inflammation in Severe Ulcerative Colitis and Its Resolution With Infliximab and Plant-based Diet as First-line Therapy.\nInflamm Bowel Dis. 2021 Jul 22. pii: 6325475. doi: 10.1093.\nSYAL G, Serrano M, Jain A, Cohen BL, et al\nInflamm Bowel Dis. 2021 Jul 19. pii: 6323888. doi: 10.1093.\nInflamm Bowel Dis. 2021 Jul 14. pii: 6321215. doi: 10.1093.\nCOATES MD, Ba DM, Liu G, Dalessio S, et al\nRevisiting the Association Between Inflammatory Bowel Disease and Parkinson's Disease.\nInflamm Bowel Dis. 2021 Jul 14. pii: 6321214. doi: 10.1093.\nSHIBUYA T, Nomura O, Nagahara A\nSafety and Efficacy of Ustekinumab for Ulcerative Colitis in a Liver Transplant Patient.\nInflamm Bowel Dis. 2021 Jul 13. pii: 6320083. doi: 10.1093.\nOJO BA, VanDussen KL, Rosen MJ\nThe Promise of Patient-Derived Colon Organoids to Model Ulcerative Colitis.\nInflamm Bowel Dis. 2021 Jul 12. pii: 6319488. doi: 10.1093.\nWEISSMAN S, Systrom HK, Aziz M, El-Dallal M, et al\nColorectal Cancer Prevention in Inflammatory Bowel Disease: A Systematic Analysis of the Overall Quality of Guideline Recommendations.\nInflamm Bowel Dis. 2021 Jul 10. pii: 6318812. doi: 10.1093.\nKHAN N, Pernes T, Weiss A, Trivedi C, et al\nEfficacy of Vedolizumab in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients.\nInflamm Bowel Dis. 2021 Jul 10. pii: 6318811. doi: 10.1093.\nTSE CS, Singh S, Sandborn WJ\nA Framework for Clinical Trials of Neurobiological Interventions That Target the Gut-Brain Axis in Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2021 Jul 9. pii: 6318240. doi: 10.1093.\nWALLDORF J, von Arnim U, Schmelz R, Riesner-Wehner A, et al\nSARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease-Fear and Desire.\nInflamm Bowel Dis. 2021 Jun 28. pii: 6310707. doi: 10.1093.\nCHOSHEN S, Turner D, Pratt LT, Precel R, et al\nInflamm Bowel Dis. 2021 Jun 21. pii: 6307118. doi: 10.1093.\nTAFT TH, Quinton S, Jedel S, Simons M, et al\nInflamm Bowel Dis. 2021 Jun 17. pii: 6301664. doi: 10.1093.\nInflamm Bowel Dis. 2021 Jun 17. pii: 6301858. doi: 10.1093.\nIBD Development After Diverticulitis May Hold Clues to IBD Pathogenesis.\nInflamm Bowel Dis. 2021;27:1172-1173.\nKARJALAINEN EK, Renkonen-Sinisalo L, Satokari R, Mustonen H, et al\nAuthor's Reply: Fecal Microbiota Transplantation for Chronic Pouchitis: Promising Novel Therapeutic or Lost Cause?\nInflamm Bowel Dis. 2021;27:e79-e80.\nHigh Fecal Proteolytic Activity That Precedes Ulcerative Colitis Likely Results From Impaired Inactivation of Pancreatic Proteases Rather Than Bacteria.\nInflamm Bowel Dis. 2021 Jun 14. pii: 6298410. doi: 10.1093.\nGALIPEAU HJ, Caminero A, Verdu EF\nIncreased Bacterial Proteolytic Activity Detected Before Diagnosis of Ulcerative Colitis.\nInflamm Bowel Dis. 2021 Jun 14. pii: 6298409. doi: 10.1093.\nLAMAZZA A, Fiori E, Carati MV, Pronio AM, et al\nSelf-Expandable Metal Stents for Refractory Complete Rectal Obstruction in Patients With Crohn Disease.\nInflamm Bowel Dis. 2021 Jun 10. pii: 6295865. doi: 10.1093.\nGONG L, Xiao J, Yi J, Xiao J, et al\nImmunomodulatory Effect of Serum Exosomes From Crohn Disease on Macrophages via Let-7b-5p/TLR4 Signaling.\nInflamm Bowel Dis. 2021 Jun 9. pii: 6295437. doi: 10.1093.\nVANDE CASTEELE N, Leighton JA, Pasha SF, Cusimano F, et al\nUtilizing Deep Learning to Analyze Whole Slide Images of Colonic Biopsies for Associations Between Eosinophil Density and Clinicopathologic Features in Active Ulcerative Colitis.\nInflamm Bowel Dis. 2021 Jun 9. pii: 6295436. doi: 10.1093.\nDAVID JG, Chute D, Reed B, Saeed S, et al\nAssessing the Prevalence of and Risk Factors for Disordered Eating Attitudes and Behaviors in Adolescents With Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2021 Jun 9. pii: 6295433. doi: 10.1093.\nJORDI SBU, Lang BM, Auschra B, von Kanel R, et al\nDepressive Symptoms Predict Clinical Recurrence of Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2021 Jun 7. pii: 6294150. doi: 10.1093.\nSelective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise.\nInflamm Bowel Dis. 2021 Jun 5. pii: 6293782. doi: 10.1093.\nMIKAIL M, Wilson A\nLow Serum Tumor Necrosis Factor-alpha Antagonist Concentrations in Patients With Inflammatory Bowel Disease Who Achieve Healing From Pyoderma Gangrenosum.\nInflamm Bowel Dis. 2021 Jun 5. pii: 6293784. doi: 10.1093.\nLUI J, Ramos GP, Codipilly DC, Katzka D, et al\nThe Use of Biologics for the Treatment of Esophageal Crohn Disease.\nInflamm Bowel Dis. 2021 May 29. pii: 6288092. doi: 10.1093.\nLI H, Shu H, Tian F\nDistinct Entity of Inflammatory Bowel Disease in Autoimmune Sclerosing Cholangitis.\nInflamm Bowel Dis. 2021 May 27. pii: 6285983. doi: 10.1093.\nGAZOULI M, Dovrolis N, Bourdakou MM, Gizis M, et al\nResponse to Anti-alpha4beta7 Blockade in Patients With Ulcerative Colitis Is Associated With Distinct Mucosal Gene Expression Profiles at Baseline.\nInflamm Bowel Dis. 2021 May 27. pii: 6285911. doi: 10.1093.\nDisparity in the Care of black Inflammatory Bowel Disease Patients.\nInflamm Bowel Dis. 2021 May 25. pii: 6284055. doi: 10.1093.\nSHAFFER SR, Erondu AI, Traboulsi C, Rai V, et al\nAchieving Histologic Normalization in Ulcerative Colitis Is Associated With a Reduced Risk of Subsequent Dysplasia.\nInflamm Bowel Dis. 2021 May 25. pii: 6284061. doi: 10.1093.\nPENA-SANCHEZ JN, Osei JA, Marques Santos JD, Jennings D, et al\nInflamm Bowel Dis. 2021 May 25. pii: 6284047. doi: 10.1093.\nMORRIS GA, McNicol M, Boyle B, Donegan A, et al\nIncreasing Biosimilar Utilization at a Pediatric Inflammatory Bowel Disease Center and Associated Cost Savings: Show Me the Money.\nInflamm Bowel Dis. 2021 May 25. pii: 6284046. doi: 10.1093.\nOLIVER BJ, Kennedy AM, van Deen WK, Weaver SA, et al\nDevelopment of Balanced Whole System Value Measures for Inflammatory Bowel Disease Care in the IBD Qorus Collaborative Using a Modified Delphi Process.\nInflamm Bowel Dis. 2021 May 25. pii: 6284056. doi: 10.1093.\nIACUCCI M, Jeffery L, Acharjee A, Nardone OM, et al\nUltra-high Magnification Endocytoscopy and Molecular Markers for Defining Endoscopic and Histologic Remission in Ulcerative Colitis-An Exploratory Study to Define Deep Remission.\nInflamm Bowel Dis. 2021 May 21. pii: 6279651. doi: 10.1093.\nSACHAN A, Srivastava S, Shah J, Singh AK, et al\nStrongyloides Stercoralis in Acute Severe Ulcerative Colitis-A Triggering Nuisance or An Opportunistic Bystander?\nInflamm Bowel Dis. 2021 May 21. pii: 6279668. doi: 10.1093.\nHUSSAMEDDIN A, Sedano R, Ramsewak D, Driman D, et al\nVedolizumab-Induced Endoscopic and Histologic Improvement in Gastric Menetrier's Disease in a Patient With Ulcerative Colitis.\nInflamm Bowel Dis. 2021 May 21. pii: 6279703. doi: 10.1093.\nHANZEL J, Jansen JM, Ter Steege RWF, Gecse KB, et al\nMultiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study.\nInflamm Bowel Dis. 2021 May 20. pii: 6278840. doi: 10.1093.\nVAN WASSENAER EA, Benninga MA, van Limbergen JL, D'Haens GR, et al\nInflamm Bowel Dis. 2021 May 20. pii: 6278841. doi: 10.1093.\nMCCURDY J, Siw KCK, Kandel R, Larrigan S, et al\nThe Effectiveness and Safety of Hyperbaric Oxygen Therapy in Various Phenotypes of Inflammatory Bowel Disease: Systematic Review With Meta-analysis.\nInflamm Bowel Dis. 2021 May 18. pii: 6277724. doi: 10.1093.\nCHEAH M, Wilson A, Solh Z, Khanna R, et al\nIgA-Mediated Warm Autoimmune Hemolytic Anemia as an Extraintestinal Manifestation in a Patient With Crohn Disease on Vedolizumab.\nInflamm Bowel Dis. 2021 May 18. pii: 6277765. doi: 10.1093.\nVERDE A, Grammegna A, Petrone E, Mastrominico A, et al\nCrohn-Like Colitis in a Young Boy With Hirschsprung Disease.\nInflamm Bowel Dis. 2021 May 18. pii: 6277720. doi: 10.1093.\nDOS SANTOS CHM, Koga GA\nResponse to the Letter to the Editor: "Pyoderma Gangrenosum in An Ulcerative Colitis Pediatric Patient During Vedolizumab Therapy Successfully Treated With Oral Cyclosporine".\nInflamm Bowel Dis. 2021 May 18. pii: 6277711. doi: 10.1093.\nGRAZIANO F, Macaluso FS, Cassata N, Citrano M, et al\nPyoderma Gangrenosum in An Ulcerative Colitis Pediatric Patient During Vedolizumab Therapy Successfully Treated With Oral Cyclosporine.\nInflamm Bowel Dis. 2021 May 18. pii: 6277715. doi: 10.1093.\nSQUIRE JD, Gonzalez-Estrada A, Caldera F, Farraye FA, et al\nCOVID-19 Vaccination in Patients With Inflammatory Bowel Disease and History of Reaction to Injectable Therapies.\nInflamm Bowel Dis. 2021 May 17. pii: 6276957. doi: 10.1093.\nDE FRIAS GOMES CG, de Almeida ASR, Mendes CCL, Ellul P, et al\nHistological Inflammation in the Endoscopically Uninflamed Mucosa is Associated With Worse Outcomes in Limited Ulcerative Colitis.\nInflamm Bowel Dis. 2021 May 17. pii: 6276940. doi: 10.1093.\nHILLEY P, Gilmore R, Srinivasan A, Choy M, et al\nCombined Targeted Treatment Using Biologic-Tofacitinib Co-Therapy in Chronic Active Ulcerative Colitis.\nInflamm Bowel Dis. 2021 May 17. pii: 6276958. doi: 10.1093.\nFASOULAS K, Stergiou E, Soufleris K\nUstekinumab for Crohn Disease With Severe Gastroduodenal Involvement.\nInflamm Bowel Dis. 2021 May 17. pii: 6276944. doi: 10.1093.\nSANTELLA C, Bitton A, Filliter C, Bessissow T, et al\nInflamm Bowel Dis. 2021 May 17. pii: 6276941. doi: 10.1093.\nCorrigendum to: Gastrointestinal Surgery for Inflammatory Bowel Disease Persistently Lowers Microbiome and Metabolome Diversity.\nInflamm Bowel Dis. 2021 May 17. pii: 6276866. doi: 10.1093.\nErratum to: Timely Monitoring of Inflammation by Fecal Lactoferrin Rapidly Predicts Therapeutic Response in Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2021 May 17. pii: 6276685. doi: 10.1093.\nTAXONERA C, Alba C, Olivares D, Martin M, et al\nInnovation in IBD Care During the COVID-19 Pandemic: Results of a Cross-Sectional Survey on Patient-Reported Experience Measures.\nInflamm Bowel Dis. 2021;27:864-869.\nGRAZIANO F, Buse M, Cassata N, Citrano M, et al\nCerebral Venous Thrombosis in a Child With Very-Early-Onset IBD.\nInflamm Bowel Dis. 2021;27:e71-e73.\nSRINIVASAN A, van Langenberg D, De Cruz P\nReal-World Effectiveness of Ustekinumab Dose Intensification in Crohn's Disease.\nInflamm Bowel Dis. 2021;27:e69.\nAHMED W, Lukin DJ\nFinding a Needle in the Haystack? Defining the Role of Random Biopsies in IBD Dysplasia Surveillance.\nInflamm Bowel Dis. 2021;27:787-790.\nTAXONERA C, Olivares D, Alba C\nInflamm Bowel Dis. 2021 May 14. pii: 6275622. doi: 10.1093.\nJAIRATH V, Guizzetti L, Baker KA, Williamson LA, et al\nImpact of COVID-19 on Inflammatory Bowel Disease Clinical Trial Recruitment: A Global Survey of Principal Investigators.\nInflamm Bowel Dis. 2021 May 14. pii: 6275617. doi: 10.1093.\nInflamm Bowel Dis. 2021 May 14. pii: 6275616. doi: 10.1093.\nDALAL RS, Mitri J, Goodrick H, Allegretti JR, et al\nReal-World Comparison of Tofacitinib vs Ustekinumab Among Bio-Exposed Patients With Ulcerative Colitis: A Propensity Score Analysis.\nInflamm Bowel Dis. 2021 May 14. pii: 6275620. doi: 10.1093.\nCLICK B, Merchea A, Colibaseanu DT, Regueiro M, et al\nIleocolic Resection for Crohn Disease: The Influence of Different Surgical Techniques on Perioperative Outcomes, Recurrence Rates, and Endoscopic Surveillance.\nInflamm Bowel Dis. 2021 May 14. pii: 6275618. doi: 10.1093.\nJENA A, Mishra S, Sachan A, Singh H, et al\nTofacitinib in Acute Severe Ulcerative Colitis: Case Series and a Systematic Review.\nInflamm Bowel Dis. 2021 May 14. pii: 6275623. doi: 10.1093.\nMCCURDY JD, Reid J, Yanofsky R, Sinnathamby V, et al\nInflamm Bowel Dis. 2021 May 14. pii: 6275627. doi: 10.1093.\nALKHAYYAT M, Abureesh M, Almomani A, Abou Saleh M, et al\nPatients With Inflammatory Bowel Disease on Treatment Have Lower Rates of Celiac Disease.\nInflamm Bowel Dis. 2021 May 14. pii: 6277368. doi: 10.1093.\nXU F, Carlson SA, Wheaton AG, Greenlund KJ, et al\nCOVID-19 Hospitalizations Among U.S. Medicare Beneficiaries With Inflammatory Bowel Disease, April 1 to July 31, 2020.\nInflamm Bowel Dis. 2021 Apr 27. pii: 6255240. doi: 10.1093.\nHYAMS JS, Brimacombe M, Haberman Y, Walters T, et al\nInflamm Bowel Dis. 2021 Apr 27. pii: 6255234. doi: 10.1093.\nRODRIGUEZ-LAGO I, Barreiro-de Acosta M\nRisk of Depression During the Natural History of Inflammatory Bowel Disease: The Phantom Menace.\nInflamm Bowel Dis. 2021 Apr 26. pii: 6179794. doi: 10.1093.\nInflamm Bowel Dis. 2021 Apr 20. pii: 6240061. doi: 10.1093.\nELTABBAKH M, Abd Alaty W, Sakr MA, Sherief AF, et al\nCommenting on the Letter (Completing the Picture in Egypt: Response to "Inflammatory Bowel Diseases in Egypt During the COVID-19 Pandemic").\nInflamm Bowel Dis. 2021;27:e66.\nGOREN G, Schwartz D, Friger M, Banai H, et al\nRandomized Controlled Trial of Cognitive-Behavioral and Mindfulness-Based Stress Reduction on the Quality of Life of Patients With Crohn Disease.\nInflamm Bowel Dis. 2021 Apr 13. pii: 6224593. doi: 10.1093.\nASONUMA K, Kobayashi T, Nakano M, Sagami S, et al\nResidual Short-Segment Distal Inflammation Has No Significant Impact on the Major Relapse of Extensive Ulcerative Colitis.\nInflamm Bowel Dis. 2021 Apr 13. pii: 6224886. doi: 10.1093.\nSCARALLO L, Bolasco G, Barp J, Bianconi M, et al\nAnti-Tumor Necrosis Factor-Alpha Withdrawal in Children With Inflammatory Bowel Disease in Endoscopic and Histologic Remission.\nInflamm Bowel Dis. 2021 Apr 9. pii: 6218764. doi: 10.1093.\nHERNANDEZ J, Rouille E, Chocteau F, Allard M, et al\nInflamm Bowel Dis. 2021 Mar 30. pii: 6203397. doi: 10.1093.\nFANG J, Wang H, Xue Z, Cheng Y, et al\nPPARgamma: The Central Mucus Barrier Coordinator in Ulcerative Colitis.\nInflamm Bowel Dis. 2021 Mar 27. pii: 6192824. doi: 10.1093.\nSHAH KP, Triana AJ, Gusdorf RE, McCoy AB, et al\nDemographic Factors Associated With Successful Telehealth Visits in Inflammatory Bowel Disease Patients.\nInflamm Bowel Dis. 2021 Mar 26. pii: 6188947. doi: 10.1093.\nKLUSMANN B, Fleer J, Tovote KA, Weersma RK, et al\nInflamm Bowel Dis. 2021 Mar 26. pii: 6188945. doi: 10.1093.\nSTIDHAM RW, Liu Y, Enchakalody B, Van T, et al\nThe Use of Readily Available Longitudinal Data to Predict the Likelihood of Surgery in Crohn Disease.\nInflamm Bowel Dis. 2021 Mar 26. pii: 6188946. doi: 10.1093.\nZHANG T, Xu Y, Yao Y, Jin L, et al\nRandomized Controlled Trial: Perioperative Dexamethasone Reduces Excessive Postoperative Inflammatory Response and Ileus After Surgery for Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2021 Mar 22. pii: 6179795. doi: 10.1093.\nSANDS BE, Long MD, Reinisch W, Panes J, et al\nInflamm Bowel Dis. 2021 Mar 20. pii: 6179119. doi: 10.1093.\nHit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2021 Mar 20. pii: 6179114. doi: 10.1093.\nKHORSHID M, AbdAllah M\nCompleting the Picture in Egypt: Response to "Inflammatory Bowel Diseases in Egypt During the COVID-19 Pandemic".\nInflamm Bowel Dis. 2021;27:e39.\nWINTER RW, Ananthakrishnan A, Burke KE, Kochar B, et al\nTime to Negative SARS-CoV-2 PCR Should Not Delay Care Among Patients With Inflammatory Bowel Diseases.\nInflamm Bowel Dis. 2021;27:590-592.\nAGRAWAL M, Brenner EJ, Zhang X, Modesto I, et al\nInflamm Bowel Dis. 2021;27:585-589.\nSANTANA GO, de Santana AC, Pfeilsticker VB\nIleum Perforation in Crohn's Disease Patient During SARS-Cov-2 Infection.\nInflamm Bowel Dis. 2021;27:e42.\nPAUWELS RWM, Proietti E, van der Woude CJ, Oudijk L, et al\nInflamm Bowel Dis. 2021 Mar 11. pii: 6168345. doi: 10.1093.\nBHAT S, Caldera F, Farraye FA\nBarriers to Administering Vaccines in Inflammatory Bowel Disease Centers.\nInflamm Bowel Dis. 2021 Mar 11. pii: 6168341. doi: 10.1093.\nZAIATZ BITTENCOURT V, Jones F, Doherty G, Ryan EJ, et al\nTargeting Immune Cell Metabolism in the Treatment of Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2021 Mar 10. pii: 6166277. doi: 10.1093.\nXIANG BJ, Huang YH, Dai C\nInflamm Bowel Dis. 2021 Mar 9. pii: 6163199. doi: 10.1093.\nSCHMOYER CJ, Saidman J, Bohl JL, Bierly CL, et al\nThe Pathogenesis and Clinical Management of Stricturing Crohn Disease.\nInflamm Bowel Dis. 2021 Mar 9. pii: 6163204. doi: 10.1093.\nANDERSON A, Cherfane C, Click B, Ramos-Rivers C, et al\nMonocytosis Is a Biomarker of Severity in Inflammatory Bowel Disease: Analysis of a 6-Year Prospective Natural History Registry.\nInflamm Bowel Dis. 2021 Mar 9. pii: 6163208. doi: 10.1093.\nTAKAHASHI H, Ogawa M, Hoshina T, Kusuhara K, et al\nMultiple Nodules in the Kidney and Spleen Presenting as the Initial Manifestation of Crohn Disease.\nInflamm Bowel Dis. 2021 Mar 9. pii: 6163180. doi: 10.1093.\nVERSTOCKT S, Verstockt B, Machiels K, Vancamelbeke M, et al\nOncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2021 Feb 24. pii: 6148910. doi: 10.1093.\nNASSANI N, Sweiss N, Berry JT, Calhoun C, et al\nLeukocytoclastic Vasculitis in Cutaneous Crohn Disease in the Setting of COVID-19.\nInflamm Bowel Dis. 2021 Feb 22. pii: 6146239. doi: 10.1093.\nIMPERATORE N, Bennato R, D'Avino A, Lombardi G, et al\nSARS-CoV-2 as a Trigger for De Novo Ulcerative Colitis.\nInflamm Bowel Dis. 2021 Feb 22. pii: 6146240. doi: 10.1093.\nBORGHINI R, Vescovo M, Giordano C, Donato G, et al\nOnset of Suspected Ulcerative Colitis After Treatment With Tocilizumab in Patient With Celiac Disease and Juvenile Idiopathic Arthritis.\nInflamm Bowel Dis. 2021 Feb 22. pii: 6146241. doi: 10.1093.\nMORILLA I, Uzzan M, Cazals-Hatem D, Colnot N, et al\nComputational Learning of microRNA-Based Prediction of Pouchitis Outcome After Restorative Proctocolectomy in Patients With Ulcerative Colitis.\nInflamm Bowel Dis. 2021 Feb 20. pii: 6145454. doi: 10.1093.\nCHIARELLA-REDFERN H, Lee S, Jubran B, Sharifi N, et al\nSuboptimal Vaccination Administration in Mothers With Inflammatory Bowel Disease and Their Biologic-Exposed Infants.\nInflamm Bowel Dis. 2021 Feb 20. pii: 6145400. doi: 10.1093.\nMIRANDA-BAUTISTA J, Rodriguez-Feo JA, Puerto M, Lopez-Cauce B, et al\nInflamm Bowel Dis. 2021 Feb 20. pii: 6145399. doi: 10.1093.\nReal-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis.\nInflamm Bowel Dis. 2021 Feb 15. pii: 6136180. doi: 10.1093.\nPANES J, Lindsay JO, Teich N, Lindgren S, et al\nColectomy Incidence Rates in Five-Year Data From the Observational Postmarketing Ulcerative Colitis Study of Originator Infliximab.\nInflamm Bowel Dis. 2021 Feb 12. pii: 6134175. doi: 10.1093.\nDHARMASIRI S, Garrido-Martin EM, Harris RJ, Bateman AC, et al\nHuman Intestinal Macrophages Are Involved in the Pathology of Both Ulcerative Colitis and Crohn Disease.\nInflamm Bowel Dis. 2021 Feb 11. pii: 6133075. doi: 10.1093.\nUstekinumab Dose Optimization in Crohn Disease: One Size Does Not Fit All.\nInflamm Bowel Dis. 2021 Feb 11. pii: 6133071. doi: 10.1093.\nJUDGE C, Saeidi R, Sugrue K, Rabbitt L, et al\nCombining Therapies in Inflammatory Bowel Disease: End of the Line or a New Era?\nInflamm Bowel Dis. 2021 Feb 5. pii: 6129139. doi: 10.1093.\nMAHMMOD S, Schultheiss JPD, van Bodegraven AA, Dijkstra G, et al\nInflamm Bowel Dis. 2021 Feb 4. pii: 6128461. doi: 10.1093.\nBHURWAL A, Minacapelli CD, Patel A, Mutneja H, et al\nEvaluation of a U.S. National Cohort to Determine Utilization in Colectomy Rates for Ulcerative Colitis Among Ethnicities.\nInflamm Bowel Dis. 2021 Feb 3. pii: 6127293. doi: 10.1093.\nDUBINSKY MC, Watanabe K, Molander P, Peyrin-Biroulet L, et al\nInflamm Bowel Dis. 2021 Feb 2. pii: 6126719. doi: 10.1093.\nBALDAN-MARTIN M, Chaparro M, Gisbert JP\nTissue Proteomic Approaches to Understand the Pathogenesis of Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2021 Feb 2. pii: 6126723. doi: 10.1093.\nGARG R, Mohammed A, Singh A, Regueiro M, et al\nInflamm Bowel Dis. 2021 Feb 2. pii: 6126191. doi: 10.1093.\nRUBIN DT, Sninsky C, Siegmund B, Sans M, et al\nInternational Perspectives on Management of Inflammatory Bowel Disease: Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPS Survey.\nInflamm Bowel Dis. 2021 Jan 29. pii: 6123676. doi: 10.1093.\nROBERTSON AR, Arnott ID\nHow Can We Predict Who Would Benefit From a Small-Bowel Capsule Endoscopy When Staging Crohn Disease?\nInflamm Bowel Dis. 2021 Jan 29. pii: 6123688. doi: 10.1093.\nCorrigendum to: Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies.\nInflamm Bowel Dis. 2021 Jan 29. pii: 6123652. doi: 10.1093.\nSHAH J, Shah A, Hassman L, Gutierrez A, et al\nOcular Manifestations of Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2021 Jan 27. pii: 6121235. doi: 10.1093.\nCHUGH R, Kroner PT, Farraye FA, Ginsburg PM, et al\nSmall-Bowel Lymphoma Mimicking Crohn Disease: A Case Series.\nInflamm Bowel Dis. 2021 Jan 27. pii: 6121236. doi: 10.1093.\nDE SIRE R, Castiglione F, Picardi M, Mascolo M, et al\nChemotherapy-Induced Remission of Steroid-Dependent Ulcerative Colitis Associated With Rectal Hodgkin Lymphoma.\nInflamm Bowel Dis. 2021 Jan 27. pii: 6121229. doi: 10.1093.\nSORRENTINO D, Gray JM\nTimely Monitoring of Inflammation by Fecal Lactoferrin Rapidly Predicts Therapeutic Response in Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2021 Jan 27. pii: 6121238. doi: 10.1093.\nSUZUKI K, Kakuta Y, Naito T, Takagawa T, et al\nInflamm Bowel Dis. 2021 Jan 27. pii: 6121230. doi: 10.1093.\nSEDANO R, Jairath V\nTofacitinib for the Treatment of Three Immune-mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata.\nInflamm Bowel Dis. 2021 Jan 23. pii: 6114619. doi: 10.1093.\nHigh-Dose Rescue Tofacitinib Prevented Inpatient Colectomy in Acute Severe Ulcerative Colitis Refractory to Anti-TNF.\nInflamm Bowel Dis. 2021 Jan 23. pii: 6114620. doi: 10.1093.\nBURKE KE, Kochar B, Allegretti JR, Winter RW, et al\nInflamm Bowel Dis. 2021;27:155-161.\nHASHASH JG, Jabak S, Francis FF, Regueiro M, et al\nShould We Be Screening for SARS-CoV-2 in IBD Patients Before Initiation of Biologic Therapy?\nInflamm Bowel Dis. 2021;27:291-294.\nBRAMUZZO M, Lionetti P, Miele E, Romano C, et al\nInflamm Bowel Dis. 2021 Jan 16. pii: 6102415. doi: 10.1093.\nDI NARDO G, Quitadamo P, Quatrini M, Malfona F, et al\nAutoimmune Hemolitic Anemia in a Boy With Inactive Ulcerative Colitis.\nInflamm Bowel Dis. 2021 Jan 16. pii: 6102424. doi: 10.1093.\nTA AD, Ollberding NJ, Karns R, Haberman Y, et al\nInflamm Bowel Dis. 2021 Jan 16. pii: 6102412. doi: 10.1093.\nROY PALADHI U, Harb AH, Daniel SG, Dawwas GK, et al\nThe Impact of Introducing Patient-Reported Inflammatory Bowel Disease Symptoms via Electronic Survey on Clinic Visit Length, Patient and Provider Satisfaction, and the Environment Microbiome.\nInflamm Bowel Dis. 2021 Jan 16. pii: 6102417. doi: 10.1093.\nCHANDE N, Singh S, Narula N, Gordon M, et al\nMedical Management Following Surgical Therapy in Inflammatory Bowel Disease: Evidence from Cochrane Reviews.\nInflamm Bowel Dis. 2021 Jan 16. pii: 6102409. doi: 10.1093.\nWEIMERS P, Ankersen DV, Lokkegaard ECL, Burisch J, et al\nOccurrence of Colorectal Cancer and the Influence of Medical Treatment in Patients With Inflammatory Bowel Disease: A Danish Nationwide Cohort Study, 1997 to 2015.\nInflamm Bowel Dis. 2021 Jan 7. pii: 6067198. doi: 10.1093.\nLI N, Zhan S, Tian Z, Liu C, et al\nAlterations in Bile Acid Metabolism Associated With Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2021 Jan 5. pii: 6063290. doi: 10.1093.\nREGENSBURGER D, Tenkerian C, Purzer V, Schmid B, et al\nMatricellular Protein SPARCL1 Regulates Blood Vessel Integrity and Antagonizes Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2021 Jan 4. pii: 6061405. doi: 10.1093.\nFOULON A, Pichois R, Sabbagh C, Fumery M, et al\nBowel Endometriosis Mimicking Crohn Disease.\nInflamm Bowel Dis. 2021 Jan 4. pii: 6061378. doi: 10.1093.\nPUGLIESE D, Schepis T, Bove V, Privitera G, et al\nMorbidly Obese Patient With Ulcerative Colitis Treated With Endoscopic Gastroplasty: A Case Report.\nInflamm Bowel Dis. 2021 Jan 4. pii: 6061374. doi: 10.1093.\nKOCHHAR GS, Mohan BP, Khan SR, Chandan S, et al\nHepatitis-B Vaccine Response in Inflammatory Bowel Disease Patients: A Systematic Review and Meta-analysis.\nInflamm Bowel Dis. 2021 Jan 4. pii: 6061413. doi: 10.1093.\nHONG S, Zaki TA, Main M, Hine AM, et al\nComparative Evaluation of Conventional Stool Testing and Multiplex Molecular Panel in Outpatients With Relapse of Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2021 Jan 2. pii: 6058972. doi: 10.1093.\nSCHARRER S, Primas C, Eichinger S, Tonko S, et al\nInflamm Bowel Dis. 2021 Jan 2. pii: 6058971. doi: 10.1093.\nBAR-GIL SHITRIT A, Ben-Horin S, Mishael T, Hoyda A, et al\nDetection of Ustekinumab in Breast Milk of Nursing Mothers With Crohn Disease.\nInflamm Bowel Dis. 2021 Jan 2. pii: 6058989. doi: 10.1093.\nJEON Y, Limketkai BN\nImplications of Dietary Impact on Hepatic Steatosis and IBD.\nInflamm Bowel Dis. 2021;27:10-11.\nPENRICE DD, Kamboj AK, Simonetto DA\nInfliximab-induced Liver Injury: A Common Link Between Crohn's Disease and Acute Liver Injury.\nInflamm Bowel Dis. 2021;27:e7-e8.\nREINISCH W, Gecse K, Halfvarson J, Irving PM, et al\nInflamm Bowel Dis. 2021;27:106-122.\nRIPOLLES T, Poza J, Suarez Ferrer C, Martinez-Perez MJ, et al\nEvaluation of Crohn's Disease Activity: Development of an Ultrasound Score in a Multicenter Study.\nInflamm Bowel Dis. 2021;27:145-154.\nOLAISEN M, Flatberg A, Granlund AVB, Royset ES, et al\nBacterial Mucosa-associated Microbiome in Inflamed and Proximal Noninflamed Ileum of Patients With Crohn's Disease.\nInflamm Bowel Dis. 2021;27:12-24.\nCHICCO F, Magri S, Cingolani A, Paduano D, et al\nInflamm Bowel Dis. 2021;27:1-9.\nCALDERA F, Ley D, Hayney MS, Farraye FA, et al\nOptimizing Immunization Strategies in Patients with IBD.\nInflamm Bowel Dis. 2021;27:123-133.\nARVANITIS M, Hart LC, DeWalt DA, Diaz-Gonzalez de Ferris ME, et al\nInflamm Bowel Dis. 2021;27:49-57.\nSZIGETHY E, Murphy SM, Ehrlich OG, Engel-Nitz NM, et al\nInflamm Bowel Dis. 2021;27:40-48.\nSEGAL JP, Askari A, Clark SK, Hart AL, et al\nInflamm Bowel Dis. 2021;27:34-39.\nVASSEUR P, Dugelay E, Benamouzig R, Savoye G, et al\nDietary Patterns, Ultra-processed Food, and the Risk of Inflammatory Bowel Diseases in the NutriNet-Sante Cohort.\nInflamm Bowel Dis. 2021;27:65-73.\nHIRTEN RP, Danieletto M, Scheel R, Shervey M, et al\nLongitudinal Autonomic Nervous System Measures Correlate With Stress and Ulcerative Colitis Disease Activity and Predict Flare.\nInflamm Bowel Dis. 2020 Dec 31. pii: 6056323. doi: 10.1093.\nHASOSAH M, Alqahtani A, Almehaidib A, Qurashi M, et al\nCongenital Chloride Diarrhea and Childhood Inflammatory Bowel Disease: A Multicenter Case Series.\nInflamm Bowel Dis. 2020 Dec 30. pii: 6055672. doi: 10.1093.\nBORREN NZ, Long MD, Sandler RS, Ananthakrishnan AN, et al\nLongitudinal Trajectory of Fatigue in Patients With Inflammatory Bowel Disease: A Prospective Study.\nInflamm Bowel Dis. 2020 Dec 25. pii: 6047698. doi: 10.1093.\nMore Epidemiological Studies Warranted to Determine the Cause of Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 Dec 17. pii: 6040645. doi: 10.1093.\nCURTIS JR, Regueiro M, Yun H, Su C, et al\nTofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan(R) Administrative Claims Database With Tofacitinib Trial Data.\nInflamm Bowel Dis. 2020 Dec 16. pii: 6039005. doi: 10.1093.\nDWADASI S, Zafer M, Goens D, Paknikar R, et al\nInpatient Therapy With Calcineurin Inhibitors in Severe Ulcerative Colitis.\nInflamm Bowel Dis. 2020 Dec 15. pii: 6034840. doi: 10.1093.\nPARIAN AM, Limketkai BN, Chowdhury R, Brewer GG, et al\nSerrated Epithelial Change Is Associated With High Rates of Neoplasia in Ulcerative Colitis Patients: A Case-controlled Study and Systematic Review With Meta-analysis.\nInflamm Bowel Dis. 2020 Dec 9. pii: 6028664. doi: 10.1093.\nMELO FJ, Pinto-Lopes P, Estevinho MM, Magro F, et al\nThe Role of Dipeptidyl Peptidase 4 as a Therapeutic Target and Serum Biomarker in Inflammatory Bowel Disease: A Systematic Review.\nInflamm Bowel Dis. 2020 Dec 9. pii: 6028655. doi: 10.1093.\nLEE C, Hong SN, Kim ER, Chang DK, et al\nDepletion of Intestinal Stem Cell Niche Factors Contributes to the Alteration of Epithelial Differentiation in SAMP1/YitFcsJ Mice With Crohn Disease-Like Ileitis.\nInflamm Bowel Dis. 2020 Dec 4. pii: 6020062. doi: 10.1093.\nBERNSTEIN CN, Hitchon CA, Walld R, Bolton JM, et al\nThe Impact of Psychiatric Comorbidity on Health Care Utilization in Inflammatory Bowel Disease: A Population-based Study.\nInflamm Bowel Dis. 2020 Dec 4. pii: 6020061. doi: 10.1093.\nLEE SH, Walshe M, Oh EH, Hwang SW, et al\nEarly Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment.\nInflamm Bowel Dis. 2020 Dec 3. pii: 6017554. doi: 10.1093.\nBATTAT R, Lukin D, Scherl EJ, Pola S, et al\nImmunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 Nov 30. pii: 6012174. doi: 10.1093.\nBAMBA S, Inatomi O, Takahashi K, Morita Y, et al\nAssessment of Body Composition From CT Images at the Level of the Third Lumbar Vertebra in Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 Nov 25. pii: 6000807. doi: 10.1093.\nYOON H, Jangi S, Dulai PS, Boland BS, et al\nInflamm Bowel Dis. 2020 Nov 25. pii: 6000793. doi: 10.1093.\nDIMOPOULOS C, Al-Bawardy B\nSARS-CoV-2 Infection and Dual-Biologic Therapy for Crohn's Disease.\nInflamm Bowel Dis. 2020;26:e153-e154.\nUR RAHMAN A, Hussain I, Hasan B, Ur Rashid M, et al\nAssociation of Complicated Diverticulitis With Development of De Novo Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 Nov 18. pii: 5987626. doi: 10.1093.\nBROMS G, Friedman S, Kim SC, Wood ME, et al\nInflamm Bowel Dis. 2020 Nov 18. pii: 5987622. doi: 10.1093.\nGEEM D, Kugathasan S\nIt Takes Two to Make It Right: Dual Biologic and Small Molecule Therapy for Treatment-Refractory Pediatric Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 Nov 17. pii: 5984956. doi: 10.1093.\nInflamm Bowel Dis. 2020 Nov 17. pii: 5985000. doi: 10.1093.\nATTAUABI M, Burisch J, Seidelin JB\nEfficacy of Ustekinumab for Active Perianal Fistulizing Crohn Disease: A Double-Center Cohort Study.\nInflamm Bowel Dis. 2020 Nov 17. pii: 5985019. doi: 10.1093.\nGONZALEZ-BERNARDO O, Riestra S, Vivas S, de Francisco R, et al\nChromoendoscopy With Indigo Carmine vs Virtual Chromoendoscopy (iSCAN 1) for Neoplasia Screening in Patients With Inflammatory Bowel Disease: A Prospective Randomized Study.\nInflamm Bowel Dis. 2020 Nov 10. pii: 5970332. doi: 10.1093.\nBRETON J, Witmer CM, Zhang Y, Downing M, et al\nUtilization of an Electronic Medical Record-integrated Dashboard Improves Identification and Treatment of Anemia and Iron Deficiency in Pediatric Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 Nov 9. pii: 5962204. doi: 10.1093.\nSHIRWAIKAR THOMAS A, Criss ZK, Shroyer NF, Abraham BP, et al\nVitamin D Receptor Gene Single Nucleotide Polymorphisms and Association With Vitamin D Levels and Endoscopic Disease Activity in Inflammatory Bowel Disease Patients: A Pilot Study.\nInflamm Bowel Dis. 2020 Nov 9. pii: 5962201. doi: 10.1093.\nRAMOS GP, Dimopoulos C, McDonald NM, Janssens LP, et al\nInflamm Bowel Dis. 2020 Nov 9. pii: 5962203. doi: 10.1093.\nSIVASAILAM B, Manski S, Wentz A, Cross RK, et al\nPresence of Obstructive Symptoms and Absence of Perianal Crohn Disease Is Predictive of Surgery After Endoscopic Balloon Dilation.\nInflamm Bowel Dis. 2020 Nov 9. pii: 5962193. doi: 10.1093.\nCORDES F, Lenker E, Weinhage T, Spille LJ, et al\nImpaired IFN-gamma-dependent STAT3 Activation Is Associated With Dysregulation of Regulatory and Inflammatory Signaling in Monocytes of Ulcerative Colitis Patients.\nInflamm Bowel Dis. 2020 Nov 9. pii: 5962195. doi: 10.1093.\nSLEUTJES JAM, de Vries AC, van der Woude CJ, Roeters van Lennep JE, et al\nLipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management.\nInflamm Bowel Dis. 2020 Nov 6. pii: 5957728. doi: 10.1093.\nHALLORAN BP, Jamil LH, Lo SK, Reeson M, et al\nInflamm Bowel Dis. 2020 Nov 6. pii: 5957726. doi: 10.1093.\nALLEGRETTI JR, Kelly CR, Grinspan A, Mullish BH, et al\nInflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection.\nInflamm Bowel Dis. 2020 Nov 6. pii: 5957723. doi: 10.1093.\nBRUCKNER RS, Spalinger MR, Barnhoorn MC, Feakins R, et al\nContribution of CD3+CD8- and CD3+CD8+ T Cells to TNF-alpha Overexpression in Crohn Disease-Associated Perianal Fistulas and Induction of Epithelial-Mesenchymal Transition in HT-29 Cells.\nInflamm Bowel Dis. 2020 Nov 4. pii: 5955654. doi: 10.1093.\nBLOOMFELD RS, Bickston SJ\nFinancial Toxicity in People With Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 Nov 4. pii: 5955755. doi: 10.1093.\nDOLINGER MT, Spencer EA, Lai J, Dunkin D, et al\nDual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 Oct 30. pii: 5944028. doi: 10.1093.\nRUBIN DT, Griffith J, Zhang Q, Hepp Z, et al\nThe Impact of Intestinal Complications on Health Care Costs Among Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Therapies.\nInflamm Bowel Dis. 2020 Oct 27. pii: 5940811. doi: 10.1093.\nBEHZAD C, Taheri H, Kashifard M\nEstablishing Safe Out-of-Hospital Infusion Centers May Improve the Quality of Care in Patients With IBD During the COVID-19 Pandemic.\nInflamm Bowel Dis. 2020;26:e140.\nHORRIGAN JM, Siegel CA, Tadros M\nManagement of IBD Patients Who Are Unwilling or Unable to Receive Infusion Therapy During the COVID-19 Pandemic.\nInflamm Bowel Dis. 2020;26:e137.\nELTABBAKH MM, Shamkh MAA, Bassuny AN, Abd Alaty WH, et al\nInflammatory Bowel Diseases in Egypt During the COVID-19 Pandemic.\nInflamm Bowel Dis. 2020;26:1771-1778.\nMATSUMOTO K, Urabe Y, Oka S, Inagaki K, et al\nInflamm Bowel Dis. 2020 Oct 22. pii: 5934978. doi: 10.1093.\nFERREIRA-DUARTE M, Estevinho MM, Duarte-Araujo M, Magro F, et al\nInflamm Bowel Dis. 2020 Oct 16. pii: 5925264. doi: 10.1093.\nRUBIN DT, Hart A, Panaccione R, Armuzzi A, et al\nInflamm Bowel Dis. 2020 Oct 15. pii: 5924202. doi: 10.1093.\nKE J, He R, Hou X\nReply to the Letter: Gut Microbiota-mediated Pleiotropic Effects of Fucose Can Improve Inflammatory Bowel Disease by Modulating Bile Acid Metabolism and Enhancing Propionate Production.\nInflamm Bowel Dis. 2020 Oct 14. pii: 5923156. doi: 10.1093.\nALKHAYYAT M, Abureesh M, Gill A, Khoudari G, et al\nLower Rates of Colorectal Cancer in Patients With Inflammatory Bowel Disease Using Anti-TNF Therapy.\nInflamm Bowel Dis. 2020 Oct 14. pii: 5923165. doi: 10.1093.\nVANDE CASTEELE N, Feagan BG, Wolf DC, Pop A, et al\nInflamm Bowel Dis. 2020 Oct 14. pii: 5923164. doi: 10.1093.\nDE FREITAS LF, Feitosa MR, Feres O, Parra RS, et al\nCutaneous Vasculitis Associated With Vedolizumab in Ulcerative Colitis.\nInflamm Bowel Dis. 2020 Oct 13. pii: 5922392. doi: 10.1093.\nCHEN G, Lissoos T, Dieyi C, Null KD, et al\nDevelopment and Validation of an Inflammatory Bowel Disease Severity Index Using US Administrative Claims Data: A Retrospective Cohort Study.\nInflamm Bowel Dis. 2020 Oct 12. pii: 5920980. doi: 10.1093.\nThe Challenge of Treating Pyoderma Gangrenosum in a Patient With Crohn Disease Based on Poor Scientific Evidence.\nInflamm Bowel Dis. 2020 Oct 12. pii: 5920985. doi: 10.1093.\nTRINDADE IA, Ferreira NB\nCOVID-19 Pandemic's Effects on Disease and Psychological Outcomes of People With Inflammatory Bowel Disease in Portugal: A Preliminary Research.\nInflamm Bowel Dis. 2020 Oct 12. pii: 5920974. doi: 10.1093.\nMARKOVIC S, Ivanovski TK, Zogovic B, Cvetkovic M, et al\nBiological Therapy for Inflammatory Bowel Disease During the COVID-19 Pandemic: Experiences From a Tertiary IBD Service.\nInflamm Bowel Dis. 2020 Oct 12. pii: 5920986. doi: 10.1093.\nFANTINI MC, Biancone L, Dragoni G, Bezzio C, et al\nInflamm Bowel Dis. 2020 Oct 8. pii: 5919368. doi: 10.1093.\nFANG X, Vazquez-Baeza Y, Elijah E, Vargas F, et al\nInflamm Bowel Dis. 2020 Oct 7. pii: 5918916. doi: 10.1093.\nSlc26a3 (DRA) in the Gut: Expression, Function, Regulation, Role in Infectious Diarrhea and Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 Sep 29. pii: 5912727. doi: 10.1093.\nPEMMASANI G, Elgendy I, Mamas MA, Leighton JA, et al\nEpidemiology and Clinical Outcomes of Patients With Inflammatory Bowel Disease Presenting With Acute Coronary Syndrome.\nInflamm Bowel Dis. 2020 Sep 26. pii: 5911943. doi: 10.1093.\nKUROWSKI JA, Achkar JP, Gupta R, Barbur I, et al\nAdipokine Resistin Levels at Time of Pediatric Crohn Disease Diagnosis Predict Escalation to Biologic Therapy.\nInflamm Bowel Dis. 2020 Sep 26. pii: 5911945. doi: 10.1093.\nSINH P, Cross R\nCardiovascular Risk Assessment and Impact of Medications on Cardiovascular Disease in Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 Sep 26. pii: 5911946. doi: 10.1093.\nSANDBORN WJ, Feagan BG, Danese S, O'Brien CD, et al\nSafety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies.\nInflamm Bowel Dis. 2020 Sep 23. pii: 5910238. doi: 10.1093.\nVIGANO C, Massironi S, Pirola L, Cristoferi L, et al\nInflamm Bowel Dis. 2020 Sep 19. pii: 5908896. doi: 10.1093.\nHONAP S, Cookson H, Sharma E, Samaan MA, et al\nTofacitinib for the Treatment of Ulcerative Colitis, Alopecia Universalis, and Atopic Dermatitis: One Drug, Three Diseases.\nInflamm Bowel Dis. 2020 Sep 18. pii: 5908061. doi: 10.1093.\nCASTELLINI G, Savarese M, Leone S, Previtali E, et al\nItalian IBD Patients Coping With Covid-19 Emergency: The Mitigating Role of Psychological Readiness to Engage in Self-care.\nInflamm Bowel Dis. 2020;26:e130-e131.\nOCCHIPINTI V, Sociale OR, Pastorelli L\nResponse to "Italian IBD Patients Coping With COVID-19 Emergency: The Mitigating Role of Psychological Readiness to Engage in Self-Care".\nInflamm Bowel Dis. 2020;26:e123.\nRIMONDI A, Tontini GE, Mazza S, Caprioli F, et al\nFogging IBD Management: An Unusual Case of IBD Flare-up During the COVID-19 Outbreak.\nInflamm Bowel Dis. 2020;26:e128-e129.\nBURGUENO JF, Abreu MT\nReply to the Letter to the Editor: The Incidence and Outcomes of COVID-19 in Patients With IBD: A Rapid Review and Meta-Analysis.\nInflamm Bowel Dis. 2020;26:e127.\nAZIZ M, Fatima R, Haghbin H, Lee-Smith W, et al\nThe Incidence and Outcomes of COVID-19 in IBD Patients: A Rapid Review and Meta-analysis.\nInflamm Bowel Dis. 2020;26:e132-e133.\nCLOUGH JN, Hill KL, Duff A, Sharma E, et al\nInflamm Bowel Dis. 2020;26:e125-e126.\nNAVANEETHAN U, LehnerNoguera V\nProlonged Duration of SARS-CoV-2 Viral Positivity in a Crohn's Disease Patient.\nInflamm Bowel Dis. 2020;26:e124.\nKORNBLUTH A, Kissous-Hunt M, George J, Legnani P, et al\nManagement of Inflammatory Bowel Disease and COVID-19 in New York City 2020: The Epicenter of IBD in the First Epicenter of the Global Pandemic.\nInflamm Bowel Dis. 2020 Sep 3. pii: 5900880. doi: 10.1093.\nKOUTROUMPAKIS F, Phillips AE, Yadav D, Machicado JD, et al\nInflamm Bowel Dis. 2020 Sep 3. pii: 5900865. doi: 10.1093.\nSITKIN S, Vakhitov T, Kononova S, Skalinskaya M, et al\nGut Microbiota-Mediated Pleiotropic Effects of Fucose Can Improve Inflammatory Bowel Disease by Modulating Bile Acid Metabolism and Enhancing Propionate Production.\nInflamm Bowel Dis. 2020 Sep 3. pii: 5900883. doi: 10.1093.\nSANDS BE, Colombel JF, Ha C, Farnier M, et al\nInflamm Bowel Dis. 2020 Sep 1. pii: 5900074. doi: 10.1093.\nSYED S, Stidham RW\nPotential for Standardization and Automation for Pathology and Endoscopy in Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 Sep 1. pii: 5900066. doi: 10.1093.\nBEZZIO C, Pellegrini L, Manes G, Arena I, et al\nInflamm Bowel Dis. 2020 Sep 1. pii: 5900070. doi: 10.1093.\nALBSHESH A, Ungar B, Ben-Horin S, Eliakim R, et al\nTerminal Ileum Thickness During Maintenance Therapy Is a Predictive Marker of the Outcome of Infliximab Therapy in Crohn Disease.\nInflamm Bowel Dis. 2020 Aug 29. pii: 5898844. doi: 10.1093.\nGUERRA I, Algaba A, Jimenez L, Mar Aller M, et al\nIncidence, Clinical Characteristics, and Evolution of SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: A Single-Center Study in Madrid, Spain.\nInflamm Bowel Dis. 2020 Aug 24. pii: 5896213. doi: 10.1093.\nCOHEN BL, Gallinger ZR, Ha C, Holubar SD, et al\nInflamm Bowel Dis. 2020;26:1291-1305.\nZHANG Q, Chen D, Yang Y\nIncidence and Prevalence of Human Papilloma Virus-associated Cancers in IBD.\nInflamm Bowel Dis. 2020;26:e101.\nHU AB, Burke KE, Kochar B, Ananthakrishnan AN, et al\nInflamm Bowel Dis. 2020 Aug 19. pii: 5894187. doi: 10.1093.\nPALACIOS ARGUETA P, Salazar M, Attar B, Simons-Linares R, et al\n90-Day Specific Readmission for Clostridium difficile Infection After Hospitalization With an Inflammatory Bowel Disease Flare: Outcomes and Risk Factors.\nInflamm Bowel Dis. 2020 Aug 19. pii: 5894152. doi: 10.1093.\nMAVRAGANI CP, Nezos A, Dovrolis N, Andreou NP, et al\nInflamm Bowel Dis. 2020 Aug 19. pii: 5894175. doi: 10.1093.\nTOWNSEND T, Fiske J, Collins P, Bond A, et al\nAmbulatory Management of Acute Severe Ulcerative Colitis: A Pandemic-driven Initiative.\nInflamm Bowel Dis. 2020 Aug 19. pii: 5894170. doi: 10.1093.\nSUGIMOTO K, Fujita S, Miyazu T, Ishida N, et al\nImprovement in Ulcerative Colitis by Administration of Benralizumab for Comorbid Refractory Bronchial Asthma: A Novel Clinical Observation.\nInflamm Bowel Dis. 2020 Aug 19. pii: 5894173. doi: 10.1093.\nJOSE DA SILVA R, da Rocha Ribeiro TC, Chebli LA, Chebli JMF, et al\nAn Unexpected Cause of Headache and Splenic Lesions During Anti-TNF Therapy in Crohn Disease.\nInflamm Bowel Dis. 2020 Aug 19. pii: 5894171. doi: 10.1093.\nDUBINSKY MC, DiBonaventura M, Fan H, Bushmakin AG, et al\nInflamm Bowel Dis. 2020 Aug 14. pii: 5892619. doi: 10.1093.\nHOKAMA A, Omija H, Kishimoto K, Kinjo T, et al\nResponse to "Histopathological Mimics of Inflammatory Bowel Disease".\nInflamm Bowel Dis. 2020 Aug 14. pii: 5892558. doi: 10.1093.\nBATRA SK, Heier CR, Diaz-Calderon L, Tully CB, et al\nInflamm Bowel Dis. 2020 Aug 14. pii: 5892560. doi: 10.1093.\nBERNSTEIN CN, Ng SC, Banerjee R, Steinwurz F, et al\nInflamm Bowel Dis. 2020 Aug 14. pii: 5892568. doi: 10.1093.\nLIU C, Yuan ZY, Yuan H, Wu KX, et al\nInflamm Bowel Dis. 2020 Aug 14. pii: 5892563. doi: 10.1093.\nLIN A, Roth H, Anyane-Yeboa A, Rubin DT, et al\nPrevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.\nInflamm Bowel Dis. 2020 Aug 11. pii: 5891018. doi: 10.1093.\nBORREN NZ, Plichta D, Joshi AD, Bonilla G, et al\nInflamm Bowel Dis. 2020 Aug 7. pii: 5885066. doi: 10.1093.\nLICHTENSTEIN GR, Rogler G, Ciorba MA, Su C, et al\nTofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.\nInflamm Bowel Dis. 2020 Aug 7. pii: 5885008. doi: 10.1093.\nLO SASSO G, Khachatryan L, Kondylis A, Battey JND, et al\nInflamm Bowel Dis. 2020 Aug 7. pii: 5885057. doi: 10.1093.\nInflammatory Bowel Disease Management in a Major Referral Center During COVID-19 Pandemic.\nInflamm Bowel Dis. 2020 Aug 1. pii: 5879647. doi: 10.1093.\nMAJSTER M, Lira-Junior R, Hoog CM, Almer S, et al\nInflamm Bowel Dis. 2020 Jul 29. pii: 5877759. doi: 10.1093.\nJAGANNATH B, Lin KC, Pali M, Sankhala D, et al\nA Sweat-based Wearable Enabling Technology for Real-time Monitoring of IL-1beta and CRP as Potential Markers for Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 Jul 28. pii: 5877396. doi: 10.1093.\nSEHGAL P, Ungaro RC, Foltz C, Iacoviello B, et al\nHigh Levels of Psychological Resilience Associated With Less Disease Activity, Better Quality of Life, and Fewer Surgeries in Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 Jul 22. pii: 5874745. doi: 10.1093.\nTIAN WN, Huang YH, Dai C\nThe Effect of the COVID-19 Pandemic on the Medical Mode of Patients With Inflammatory Bowel Disease in China.\nInflamm Bowel Dis. 2020 Jul 22. pii: 5874746. doi: 10.1093.\nGREEN ME, Brahmbhatt B, Baumgarten D, Krishna M, et al\nMeckel's Diverticulum Masquerading as Crohn Disease.\nInflamm Bowel Dis. 2020 Jul 21. pii: 5874417. doi: 10.1093.\nVERDON C, Reinglas J, Coulombe J, Gonczi L, et al\nNo Change in Surgical and Hospitalization Trends Despite Higher Exposure to Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease in the Quebec Provincial Database From 1996 to 2015.\nInflamm Bowel Dis. 2020 Jul 17. pii: 5872809. doi: 10.1093.\nNAVANEETHAN U, Lourdusamy D, LehnerNoguera V, Shen B, et al\nSafety of Endoscopy in Patients With Inflammatory Bowel Disease During the COVID-19 Pandemic.\nInflamm Bowel Dis. 2020 Jul 17. pii: 5872834. doi: 10.1093.\nCRISTOBAL I, Madoz-Gurpide J, Rojo F, Garcia-Foncillas J, et al\nInflamm Bowel Dis. 2020;26:e87.\nBERINSTEIN JA, Cohen-Mekelburg SA, Steiner CA, McLeod M, et al\nVariations in Health Care Utilization Patterns Among Inflammatory Bowel Disease Patients at Risk for High Medical Service Utilization Enrolled in High Deductible Health Plans.\nInflamm Bowel Dis. 2020 Jul 17. pii: 5872817. doi: 10.1093.\nHERNANDEZ BENABE S, Langshaw AH\nIBD in the Times of COVID-19.\nInflamm Bowel Dis. 2020;26:e92.\nBAMIAS G, Lagou S, Gizis M, Karampekos G, et al\nThe Greek Response to COVID-19: A True Success Story from an IBD Perspective.\nInflamm Bowel Dis. 2020;26:1144-1148.\nClostridium Difficile and Increased Risk of Surgery in Crohn's Disease. Can Early Microbial Signatures Forecast Risk of Disease Progression?\nInflamm Bowel Dis. 2020;26:1222-1224.\nAYOUB A, Jairath V, Aldraiweesh S, Khanna R, et al\nSafety of Biologic Therapy in Octogenarians and Nonagenarians With Inflammatory Bowel Disease in Ontario: A Case Series.\nInflamm Bowel Dis. 2020 Jul 11. pii: 5870254. doi: 10.1093.\nGEORGIOU AN, Ntritsos G, Papadimitriou N, Dimou N, et al\nInflamm Bowel Dis. 2020 Jul 6. pii: 5867966. doi: 10.1093.\nDI RUSCIO M, Variola A, Angheben A, Resimini S, et al\nInflamm Bowel Dis. 2020 Jul 6. pii: 5867642. doi: 10.1093.\nGROSSBERG LB, Pellish RS, Cheifetz AS, Feuerstein JD, et al\nInflamm Bowel Dis. 2020 Jul 3. pii: 5866902. doi: 10.1093.\nCARD TR, Zittan E, Nguyen GC, Grainge MJ, et al\nInflamm Bowel Dis. 2020 Jul 3. pii: 5866856. doi: 10.1093.\nSAHU P, Kedia S, Padhan R, Ahuja V, et al\nPregnancy-Onset Inflammatory Bowel Disease (PO-IBD): A Riddle Inside an Enigma.\nInflamm Bowel Dis. 2020 Jul 3. pii: 5866857. doi: 10.1093.\nInflamm Bowel Dis. 2020 Jun 29. pii: 5864595. doi: 10.1093.\nDULAI PS, Jairath V, Zou G, Stitt LW, et al\nEarly Combined Immunosuppression May Be More Effective for Reducing Complications in Isolated Colonic- vs Ileal-Dominant Crohn Disease.\nInflamm Bowel Dis. 2020 Jun 27. pii: 5863990. doi: 10.1093.\nPEPE M, Carulli E, Forleo C, Moscarelli M, et al\nInflammatory Bowel Disease and Acute Coronary Syndromes: From Pathogenesis to the Fine Line Between Bleeding and Ischemic Risk.\nInflamm Bowel Dis. 2020 Jun 27. pii: 5863988. doi: 10.1093.\nLEE JA, Magavi PR, Konijeti GG\nTreatment of Ulcerative Colitis and Seronegative Inflammatory Spondyloarthritis With Vedolizumab and Tofacitinib.\nInflamm Bowel Dis. 2020 Jun 27. pii: 5863987. doi: 10.1093.\nAXELRAD JE, Malter L, Hong S, Chang S, et al\nFrom the American Epicenter: Coronavirus Disease 2019 in Patients with Inflammatory Bowel Disease in the New York City Metropolitan Area.\nInflamm Bowel Dis. 2020 Jun 24. pii: 5861860. doi: 10.1093.\nGRANT RK, Jones GR, Plevris N, Lynch RW, et al\nInflamm Bowel Dis. 2020 Jun 23. pii: 5861142. doi: 10.1093.\nNAKASEKO H, Nishida D, Abe N, Tanaka K, et al\nEffect of Exclusive Enteral Nutrition on Renal Function for Granulomatous Interstitial Nephritis Associated With Crohn Disease.\nInflamm Bowel Dis. 2020 Jun 22. pii: 5860630. doi: 10.1093.\nHONAP S, Pavlidis P, Ray S, Sharma E, et al\nInflamm Bowel Dis. 2020 Jun 22. pii: 5860628. doi: 10.1093.\nSCHAFER E, Shyu I, Walker C, Smallfield G, et al\nNew Presentation of Hepatic Inflammatory Pseudotumor and Crohn Disease.\nInflamm Bowel Dis. 2020 Jun 20. pii: 5860196. doi: 10.1093.\nKELSEN JR, Dawany N, Conrad MA, Karakasheva TA, et al\nInflamm Bowel Dis. 2020 Jun 19. pii: 5859746. doi: 10.1093.\nTSURUTA Y, Furuta Y, Naoe H, Tanaka M, et al\nMultiple Gastric Polyps Improved After Treatment for Ulcerative Colitis.\nInflamm Bowel Dis. 2020 Jun 18. pii: 5859375. doi: 10.1093.\nGUO L, Rohde J, Farraye FA\nStigma and Disclosure in Patients With Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020;26:1010-1016.\nGRASSIA R, Soro S, Conti CB\nInflamm Bowel Dis. 2020;26:e71.\nEditorial on Hirten et al.\nInflamm Bowel Dis. 2020;26:1059.\nInflammation of the Ileal Anal Pouch: Do Biologics Really Change the Trajectory?\nInflamm Bowel Dis. 2020;26:1087-1088.\nORTEGA MORENO L, Fernandez-Tome S, Chaparro M, Marin AC, et al\nProfiling of Human Circulating Dendritic Cells and Monocyte Subsets Discriminates Between Type and Mucosal Status in Patients With Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 Jun 17. pii: 5858322. doi: 10.1093.\nJEROME R, Sebastien H, Delphine WV, Jean-Francois E, et al\nRefractory Inflammatory Bowel Disease Associated With Sclerosing Cholangitis, Diabetes Insipidus, and Myeloid Neoplasm: Langerhans Cell Histiocytosis Was Hiding Since the Beginning.\nInflamm Bowel Dis. 2020 Jun 12. pii: 5856440. doi: 10.1093.\nSCHLABITZ F, Teich N, Michl P, Walldorf J, et al\nInflammatory Bowel Disease and COVID-19-"Preventive" Sick Certificates as a Frequent Coping Strategy in the Face of the Pandemic.\nInflamm Bowel Dis. 2020 Jun 12. pii: 5856424. doi: 10.1093.\nJOHN RA, Gearry RB\nSmoking Cessation for Patients With Crohn Disease: Not Just for the Patient?\nInflamm Bowel Dis. 2020 Jun 12. pii: 5856324. doi: 10.1093.\nCOELHO-PRABHU N, Bruining DH, Faubion WA, Kane SV, et al\nA 1-Year Cross-sectional Inflammatory Bowel Disease Surveillance Colonoscopy Cohort Comparing High-definition White Light Endoscopy and Chromoendoscopy.\nInflamm Bowel Dis. 2020 Jun 12. pii: 5856329. doi: 10.1093.\nDUZENLI T, Koseoglu H, Akyol T\nNLR and PLR as Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated with Anti-TNF.\nInflamm Bowel Dis. 2020 Jun 9. pii: 5854914. doi: 10.1093.\nBERTANI L, Costa F, Barberio B, Savarino E, et al\nReply to Letter to the Editor: NLR and PLR as Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF.\nInflamm Bowel Dis. 2020 Jun 9. pii: 5854915. doi: 10.1093.\nLIU B, Yang MQ, Yu TY, Yin YY, et al\nMast Cell Tryptase Promotes Inflammatory Bowel Disease-Induced Intestinal Fibrosis.\nInflamm Bowel Dis. 2020 Jun 8. pii: 5854445. doi: 10.1093.\nKOBAYASHI Y, Ohfuji S, Kondo K, Fukushima W, et al\nAssociation of Dietary Fatty Acid Intake With the Development of Ulcerative Colitis: A Multicenter Case-Control Study in Japan.\nInflamm Bowel Dis. 2020 Jun 8. pii: 5854441. doi: 10.1093.\nTemporal, Sexual, and Geographic Distributions of the Coexistence of Ulcerative Colitis and Graves Disease.\nInflamm Bowel Dis. 2020 Jun 8. pii: 5854442. doi: 10.1093.\nMARTIN ARRANZ E, Suarez Ferrer C, Garcia Ramirez L, Rueda Garcia JL, et al\nManagement of COVID-19 Pandemic in Spanish Inflammatory Bowel Disease Units: Results From a National Survey.\nInflamm Bowel Dis. 2020 Jun 4. pii: 5851307. doi: 10.1093.\nCHUDY-ONWUGAJE K, Mamunes AP, Schwartz DA, Horst S, et al\nInflamm Bowel Dis. 2020 Jun 3. pii: 5850604. doi: 10.1093.\nPEKOW J, Patel P\nDaily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease. Reply Letter to Elia et al.\nInflamm Bowel Dis. 2020 Jun 2. pii: 5850168. doi: 10.1093.\nAspirin, NSAIDs, and Inflammatory Bowel Disease: An Exercise Physiology Perspective.\nInflamm Bowel Dis. 2020 Jun 2. pii: 5850171. doi: 10.1093.\nRAMPAL R, Wari N, Singh AK, Das U, et al\nRetinoic Acid Is Elevated in the Mucosa of Patients With Active Ulcerative Colitis and Displays a Proinflammatory Role by Augmenting IL-17 and IFNgamma Production.\nInflamm Bowel Dis. 2020 May 29. pii: 5848464. doi: 10.1093.\nNOURELDIN M, Cohen-Mekelburg S, Mahmood A, Stidham R, et al\nTrends of 5-Aminosalicylate Medication Use in Patients With Crohn Disease.\nInflamm Bowel Dis. 2020 May 29. pii: 5848467. doi: 10.1093.\nLEUNG KK, Tandon P, Govardhanam V, Maxwell C, et al\nThe Risk of Adverse Neonatal Outcomes With Maternal Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.\nInflamm Bowel Dis. 2020 May 29. pii: 5848466. doi: 10.1093.\nMURPHY LK, de la Vega R, Kohut SA, Kawamura JS, et al\nSystematic Review: Psychosocial Correlates of Pain in Pediatric Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 May 27. pii: 5847655. doi: 10.1093.\nVALDES DELGADO T, Maldonado Perez B, Castro Laria L\nErythema Nodosum: As an Extraintestinal Manifestation or Complication in Ulcerative Colitis?\nInflamm Bowel Dis. 2020 May 25. pii: 5843661. doi: 10.1093.\nKRONER PT, Lee A, Farraye FA\nRespiratory Tract Manifestations of Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 May 25. pii: 5843660. doi: 10.1093.\nQAZI T, Smith A, Alexander M, Hammer D, et al\nDisparities in Objective Sleep Quality as Assessed Through Wrist Actigraphy in Minority Patients With Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 May 25. pii: 5843655. doi: 10.1093.\nLYLES JL, Mulgund AA, Bauman LE, Su W, et al\nEffect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 May 25. pii: 5843647. doi: 10.1093.\nFASOULAS K, Kafalis N, Soufleris K\nAlphazathioprine-Induced Tremor: A Rare, Dose-Dependent Side Effect of Azathioprine in a Patient With Active Crohn Disease.\nInflamm Bowel Dis. 2020 May 23. pii: 5843195. doi: 10.1093.\nHUANG JS, Cruz R, Yueh R, Parker J, et al\nA Systemwide Electronic Health Record Checklist to Improve Comorbidity Screening of Children With Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 May 22. pii: 5841913. doi: 10.1093.\nBARASH Y, Klang E, Tau N, Ben-Horin S, et al\nEvolution of Inflammatory Bowel Disease Research From a Bird's-Eye Perspective: A Text-Mining Analysis of Publication Trends and Topics.\nInflamm Bowel Dis. 2020 May 22. pii: 5841908. doi: 10.1093.\nMARTINELLI M, Strisciuglio C, Fedele F, Miele E, et al\nInflamm Bowel Dis. 2020 May 22. pii: 5841894. doi: 10.1093.\nMINTZ MJ, Ananthakrishnan AN\nInflamm Bowel Dis. 2020 May 20. pii: 5840920. doi: 10.1093.\nDRAGONI G, De Hertogh G, Vermeire S\nThe Role of Citrullination in Inflammatory Bowel Disease: A Neglected Player in Triggering Inflammation and Fibrosis?\nInflamm Bowel Dis. 2020 May 19. pii: 5840491. doi: 10.1093.\nYU A, Friedman S, Ananthakrishnan AN\nInflamm Bowel Dis. 2020 May 19. pii: 5840482. doi: 10.1093.\nEGBERG MD, Phillips M, Galanko JA, Kappelman M, et al\nInflamm Bowel Dis. 2020 May 19. pii: 5840483. doi: 10.1093.\nRYBINSKI F, Weisser M, Niess JH, Hruz P, et al\nAmoebic Liver Abscess in Crohn Disease Treated With Ustekinumab.\nInflamm Bowel Dis. 2020 May 14. pii: 5836916. doi: 10.1093.\nBARNES EL, Bauer CM, Sandler RS, Kappelman MD, et al\nInflamm Bowel Dis. 2020 May 14. pii: 5836912. doi: 10.1093.\nROSEN MH, Axelrad J, Hudesman D, Rubin DT, et al\nInflamm Bowel Dis. 2020 May 12. pii: 5836016. doi: 10.1093.\nXU F, Chen D, Yang Y\nResponse to "Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn's Disease".\nInflamm Bowel Dis. 2020;26:e47.\nInflamm Bowel Dis. 2020;26:e46.\nSafety of Biologic Therapy in Liver Transplant Recipients: Case Closed?\nInflamm Bowel Dis. 2020;26:960.\nUtilization of Diagnostic Imaging and Ionizing Radiation Exposure-Has the Tide Already Turned?\nInflamm Bowel Dis. 2020;26:907-908.\nPredictors of Perianal Fistula Relapse in Crohn's Disease.\nInflamm Bowel Dis. 2020;26:932-933.\nKERUR B, Benchimol EI, Fiedler K, Stahl M, et al\nNatural History of Very Early Onset Inflammatory Bowel Disease in North America: A Retrospective Cohort Study.\nInflamm Bowel Dis. 2020 May 9. pii: 5835042. doi: 10.1093.\nCORRIDONI D, Chapman T, Antanaviciute A, Satsangi J, et al\nInflamm Bowel Dis. 2020 May 9. pii: 5834990. doi: 10.1093.\nGUZMAN-PRADO Y, Samson O, Segal JP, Limdi JK, et al\nInflamm Bowel Dis. 2020 May 9. pii: 5834989. doi: 10.1093.\nTURSI A, Vetrone LM, Papa A\nAnti-TNF-alpha Agents in Inflammatory Bowel Disease and Course of COVID-19.\nInflamm Bowel Dis. 2020 May 8. pii: 5831990. doi: 10.1093.\nVAN GENNEP S, Evers SW, Rietdijk ST, Gielen ME, et al\nHigh Disease Burden Drives Indirect Costs in Employed Inflammatory Bowel Disease Patients: The WORK-IBD Study.\nInflamm Bowel Dis. 2020 May 7. pii: 5831697. doi: 10.1093.\nPARK KT, Ehrlich OG, Allen JI, Meadows P, et al\nInflamm Bowel Dis. 2020 May 6. pii: 5831199. doi: 10.1093.\nJACOBS J, Clark-Snustad K, Lee S\nInflamm Bowel Dis. 2020 Apr 28. pii: 5826022. doi: 10.1093.\nFENTON CG, Taman H, Florholmen J, Sorbye SW, et al\nTranscriptional Signatures That Define Ulcerative Colitis in Remission.\nInflamm Bowel Dis. 2020 Apr 23. pii: 5823961. doi: 10.1093.\nLEVHAR N, Ungar B, Kopylov U, Fudim E, et al\nPropagation of EBV-driven Lymphomatous Transformation of Peripheral Blood B Cells by Immunomodulators and Biologics Used in the Treatment of Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 Apr 23. pii: 5823959. doi: 10.1093.\nYAO J, Jiang X, You JHS\nA Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: From Immunosuppressive to Anti-TNF Therapy.\nInflamm Bowel Dis. 2020 Apr 20. pii: 5822887. doi: 10.1093.\nLINHARES M, Ramos D, Pereira F, Azevedo R, et al\nHidradenitis Suppurativa and Crohn Disease: A Rare Association.\nInflamm Bowel Dis. 2020 Apr 18. pii: 5822088. doi: 10.1093.\nDERER S, Brethack AK, Pietsch C, Jendrek ST, et al\nInflammatory Bowel Disease-associated GP2 Autoantibodies Inhibit Mucosal Immune Response to Adherent-invasive Bacteria.\nInflamm Bowel Dis. 2020 Apr 18. pii: 5822108. doi: 10.1093.\nCorrigendum to: Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 Apr 18. pii: 5822087. doi: 10.1093.\nDPP-4 as a Novel Biomarker for Inflammatory Bowel Disease: Is It Ready for Clinical Use?\nInflamm Bowel Dis. 2020 Apr 16. pii: 5820737. doi: 10.1093.\nAntibiotics in Refractory IBD: Not Without Risks but Are the Alternatives Better? Response to Gilmore et al.\nInflamm Bowel Dis. 2020;26:e42.\nLIN S, Lin X, Li X, Chen M, et al\nMaking Qualitative Intestinal Stricture Quantitative: Embracing Radiomics in IBD.\nInflamm Bowel Dis. 2020;26:743-745.\nLEE AS, Hubers J, Osman F, Caldera F, et al\nInflamm Bowel Dis. 2020 Apr 6. pii: 5816423. doi: 10.1093.\nBERTANI L, Rossari F, Barberio B, Demarzo MG, et al\nNovel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio.\nInflamm Bowel Dis. 2020 Mar 31. pii: 5813970. doi: 10.1093.\nPATEL P, Gao G, Gulotta G, Dalal S, et al\nDaily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 Mar 27. pii: 5812729. doi: 10.1093.\nORFANOUDAKI E, Foteinogiannopoulou K, Theodoraki E, Koutroubakis IE, et al\nClinical Value of Proactive Infliximab Drug Monitoring in Patients With Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 Mar 24. pii: 5811190. doi: 10.1093.\nMCCURDY JD, Benchimol EI\nResponse to Letter, "Risk of Venous Thromboembolism After Hospital Discharge in Patients With Inflammatory Bowel Disease".\nInflamm Bowel Dis. 2020 Mar 21. pii: 5810826. doi: 10.1093.\nXIE H, Zeng D, Chen D, Tang W, et al\nLetter to the Editor: Risk of Venous Thromboembolism After Hospital Discharge in Patients With Inflammatory Bowel Disease: A Population-based Study.\nInflamm Bowel Dis. 2020 Mar 20. pii: 5810369. doi: 10.1093.\nNAYMAGON L, Tremblay D, Zubizarreta N, Moshier E, et al\nInflamm Bowel Dis. 2020 Mar 18. pii: 5809340. doi: 10.1093.\nOSTERMAN MT, Scott FI, Fogt FF, Gilroy ED, et al\nInflamm Bowel Dis. 2020 Mar 14. pii: 5805376. doi: 10.1093.\nYVELLEZ OV, Rai V, Sossenheimer PH, Hart J, et al\nInflamm Bowel Dis. 2020 Mar 10. pii: 5802337. doi: 10.1093.\nBODIWALA V, Marshall T, Das KM, Brant SR, et al\nComparison of Disease Phenotypes and Clinical Characteristics Among South Asian and White Patients with Inflammatory Bowel Disease at a Tertiary Referral Center.\nInflamm Bowel Dis. 2020 Mar 7. pii: 5799010. doi: 10.1093.\nRacial Differences in Inflammatory Bowel Disease: A Race With Alternating Winners?\nInflamm Bowel Dis. 2020 Mar 7. pii: 5799011. doi: 10.1093.\nGEORGE LA, Cross RK\nHow Do We Sequence Biologic Therapies in 2019?\nInflamm Bowel Dis. 2020;26:617-618.\nSYAL G, Melmed GY\nIs It Time For High Dose Influenza Vaccination In Inflammatory Bowel Diseases?\nInflamm Bowel Dis. 2020;26:603-605.\nInflamm Bowel Dis. 2020;26:641-642.\nLIMKETKAI BN, Gordon M, Mutlu EA, De Silva PS, et al\nInflamm Bowel Dis. 2020;26:510-514.\nBRONSWIJK M, Moens A, Lenfant M, Tops S, et al\nInflamm Bowel Dis. 2020;26:628-634.\nJANGI S, Ruan A, Korzenik J, de Silva P, et al\nSouth Asian Patients With Inflammatory Bowel Disease in the United States Demonstrate More Fistulizing and Perianal Crohn Phenotype.\nInflamm Bowel Dis. 2020 Mar 2. pii: 5771121. doi: 10.1093.\nLIN E, Katz S\nAcute Pancreatitis in a Patient With Ulcerative Colitis on Vedolizumab.\nInflamm Bowel Dis. 2020 Feb 26. pii: 5758182. doi: 10.1093.\nDAI C, Cao Q, Jiang M\nRisk of Venous Thromboembolism After Hospital Discharge in Patients with Inflammatory Bowel Disease Patients.\nInflamm Bowel Dis. 2020 Feb 25. pii: 5755895. doi: 10.1093.\nLI H, Tian F\nToxic Epidermal Necrolysis Because of Various Herpesviruses Infection After Accelerated Infliximab Induction in a Chinese Patient With Acute Severe Ulcerative Colitis.\nInflamm Bowel Dis. 2020 Feb 22. pii: 5748143. doi: 10.1093.\nLEY D, Martin B, Caldera F\nInflamm Bowel Dis. 2020 Feb 22. pii: 5748139. doi: 10.1093.\nPEVERELLE M, Mills C, Testro A, Gow P, et al\nLetter Re: Safety of Combination Biologic and Antirejection Therapy Post-liver Transplantation in Patients With Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 Feb 20. pii: 5741005. doi: 10.1093.\nOKAMOTO D, Kawai Y, Kakuta Y, Naito T, et al\nGenetic Analysis of Ulcerative Colitis in Japanese Individuals Using Population-specific SNP Array.\nInflamm Bowel Dis. 2020 Feb 19. pii: 5740361. doi: 10.1093.\nHAMDEH S, Aziz M, Altayar O, Olyaee M, et al\nEarly vs Late Use of Anti-TNFa Therapy in Adult Patients With Crohn Disease: A Systematic Review and Meta-Analysis.\nInflamm Bowel Dis. 2020 Feb 17. pii: 5739148. doi: 10.1093.\nLAW CCY, Koh D, Bao Y, Jairath V, et al\nRisk of Postoperative Infectious Complications From Medical Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.\nInflamm Bowel Dis. 2020 Feb 12. pii: 5734556. doi: 10.1093.\nPIGNICZKI D, Farkas K, Molnar T\nThe Theoretical Scenario Experienced in a Real-Life Case of Ulcerative Colitis and Associated Primary Sclerosing Cholangitis: Case 123.\nInflamm Bowel Dis. 2020 Feb 11. pii: 5733139. doi: 10.1093.\nEditorial: Risk of Cancer Development in IBD-Inflammation vs Immunosuppression.\nInflamm Bowel Dis. 2020;26:460-461.\nInflamm Bowel Dis. 2020;26:448-449.\nGARCIA MJ, Arminanzas C, Rivero M, Ramos M, et al\nCrohn's Disease and Immunosupressive Treatment: Hepatosplenic Lesions as an Atypical Case of Bartonella henselae.\nInflamm Bowel Dis. 2020;26:e17-e18.\nJUKEMA JB, Brandse JF, de Boer NKH\nSuccessful Treatment of Oral Crohn's Disease by Ustekinumab.\nInflamm Bowel Dis. 2020;26:e19.\nSAYOC-BECERRA A, Krishnan M, Fan S, Jimenez J, et al\nInflamm Bowel Dis. 2020;26:407-422.\nJUN X, Ning C, Yang S, Zhe W, et al\nInflamm Bowel Dis. 2020;26:380-390.\nCORDES F, Lenker E, Spille LJ, Weinhage T, et al\nInflamm Bowel Dis. 2020;26:391-406.\nVASUDEVAN A, Ip F, Liew D, van Langenberg DR, et al\nThe Cost-effectiveness of Initial Immunomodulators or Infliximab Using Modern Optimization Strategies for Crohn's Disease in the Biosimilar Era.\nInflamm Bowel Dis. 2020;26:369-379.\nGAINES LS, Slaughter JC, Schwartz DA, Beaulieu DB, et al\nInflamm Bowel Dis. 2020;26:423-428.\nEL-DALLAL M, Chen Y, Lin Q, Rakowsky S, et al\nInflamm Bowel Dis. 2020 Feb 8. pii: 5731339. doi: 10.1093.\nHistologic Healing in Ulcerative Colitis: Benefits. And Risks. Was Voltaire Right?\nInflamm Bowel Dis. 2020 Feb 7. pii: 5729887. doi: 10.1093.\nCARNEY H, Marrie RA, Bolton JM, Patten SB, et al\nPrevalence and Risk Factors of Substance Use Disorder in Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 Feb 6. pii: 5728525. doi: 10.1093.\nPENG Y, Thomas AS, Wei D, Tan D, et al\nAn Aggressive Approach Toward a Case of Refractory Ulcerative Colitis With Uncertain Etiology in the Context of Chronic Myeloid Leukemia.\nInflamm Bowel Dis. 2020 Feb 4. pii: 5721970. doi: 10.1093.\nJABANDZIEV P, Bohosova J, Pinkasova T, Kunovsky L, et al\nThe Emerging Role of Noncoding RNAs in Pediatric Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 Feb 3. pii: 5721205. doi: 10.1093.\nMCCURDY JD, Kuenzig ME, Smith G, Spruin S, et al\nInflamm Bowel Dis. 2020 Jan 29. pii: 5717328. doi: 10.1093.\nBAFFORD AC, Cross RK\nRisk of Venous Thromboembolism in Patients with Inflammatory Bowel Disease Extends beyond Hospitalization.\nInflamm Bowel Dis. 2020 Jan 29. pii: 5717307. doi: 10.1093.\nSZANTO KJ, Rutka M, Pigniczki D, Farkas K, et al\nSerological Status of Inflammatory Bowel Disease Patients Before Starting Biological Therapy - Data From a Tertiary Centre of the Best Vaccined Country.\nInflamm Bowel Dis. 2020 Jan 24. pii: 5715025. doi: 10.1093.\nMARTINELLI M, Miele E\nImplementation and Widespread of Inflammatory Bowel Disease Vaccination and Immunization Guidelines: Not an Easy Task.\nInflamm Bowel Dis. 2020 Jan 24. pii: 5715024. doi: 10.1093.\nLEE AA, Rao K, Limsrivilai J, Gillilland M, et al\nTemporal Gut Microbial Changes Predict Recurrent Clostridiodes Difficile Infection in Patients With and Without Ulcerative Colitis.\nInflamm Bowel Dis. 2020 Jan 23. pii: 5714595. doi: 10.1093.\nInterrogating the Gut-Brain Axis in the Context of Inflammatory Bowel Disease: A Translational Approach.\nInflamm Bowel Dis. 2020 Jan 22. pii: 5714219. doi: 10.1093.\nHOU G, Bishu S\nTh17 Cells in Inflammatory Bowel Disease: An Update for the Clinician.\nInflamm Bowel Dis. 2020 Jan 22. pii: 5714220. doi: 10.1093.\nCONRAD MA, Kelsen JR\nEditorial to Temporal Gut Microbial Changes Predict Recurrent Clostridium difficile Infection in Patients With and Without Ulcerative Colitis.\nInflamm Bowel Dis. 2020 Jan 22. pii: 5714218. doi: 10.1093.\nGUPTA N, Liu C, King E, Sylvester F, et al\nInflamm Bowel Dis. 2020 Jan 22. pii: 5714217. doi: 10.1093.\nPRATHAPAN KM, Ramos Rivers C, Anderson A, Koutroumpakis F, et al\nPeripheral Blood Eosinophilia and Long-term Severity in Pediatric-Onset Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2020 Jan 21. pii: 5711281. doi: 10.1093.\nGUBATAN J, Mehigan GA, Villegas F, Mitsuhashi S, et al\nInflamm Bowel Dis. 2020 Jan 18. pii: 5709590. doi: 10.1093.\nDIN H, Anderson AJ, Ramos Rivers C, Proksell S, et al\nDisease Characteristics and Severity in Patients With Inflammatory Bowel Disease With Coexistent Diabetes Mellitus.\nInflamm Bowel Dis. 2020 Jan 16. pii: 5707489. doi: 10.1093.\nEvaluation of EBV Status and Thiopurine Use in Pediatric Inflammatory Bowel Disease: Time to be a Standard of Care.\nInflamm Bowel Dis. 2020 Jan 16. pii: 5707490. doi: 10.1093.\nRoutine Testing for EBV Status in Children With Inflammatory Bowel Disease: Are We Overreacting?\nInflamm Bowel Dis. 2020 Jan 16. pii: 5707482. doi: 10.1093.\nKATINIOS G, Casado-Bedmar M, Walter SA, Vicario M, et al\nIncreased Colonic Epithelial Permeability and Mucosal Eosinophilia in Ulcerative Colitis in Remission Compared With Irritable Bowel Syndrome and Health.\nInflamm Bowel Dis. 2020 Jan 16. pii: 5707481. doi: 10.1093.\nPEVERELLE M, Paleri S, Hughes J, De Cruz P, et al\nActivity of Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis Predicts Poorer Clinical Outcomes.\nInflamm Bowel Dis. 2020 Jan 16. pii: 5707461. doi: 10.1093.\nWONG U, Cross RK\nAre Inflammatory Bowel Disease Patients With Diabetes Mellitus at Increased Risk for Poor Outcomes Including Greater Health Care Utilization?\nInflamm Bowel Dis. 2020 Jan 16. pii: 5707487. doi: 10.1093.\nPERRY C, Kapur N, Barrett TA\nDDP-4 as a Novel Biomarker for Inflammatory Bowel Disease: Is It Ready for Clinical Use?\nInflamm Bowel Dis. 2020 Jan 8. pii: 5698302. doi: 10.1093.\nPINTO-LOPES P, Afonso J, Pinto-Lopes R, Rocha C, et al\nInflamm Bowel Dis. 2020 Jan 8. pii: 5698249. doi: 10.1093.\nROOSENBOOM B, van Lochem EG, Smids C, Groenen MJM, et al\nInflamm Bowel Dis. 2020;26:e13.\nBAUER CM, Younis A, Herfarth H, Barnes EL, et al\nResponse to Infliximab After Loss of Response to Adalimumab in Crohn's Disease.\nInflamm Bowel Dis. 2020;26:e5.\nCASANOVA MJ, Chaparro M, Gisbert JP\nResponse to the Letter to the Editor: "Response to Infliximab After Loss of Response to Adalimumab in Crohn's Disease".\nInflamm Bowel Dis. 2020;26:e6.\nInflamm Bowel Dis. 2020;26:301-303.\nTDM of Anti-TNF Agents: The Importance of Being Active!\nInflamm Bowel Dis. 2020;26:271-272.\nCHANG S, Hamilton M, Lees C, Atreja A, et al\nMobile Health in IBD: Enhancing Care, One Phone at a Time.\nInflamm Bowel Dis. 2020;26:163-166.\nWANDERS LK, Cordes M, Voorham Q, Sie D, et al\nInflamm Bowel Dis. 2020;26:167-180.\nKARUPPUCHAMY T, Tyler CJ, Lundborg LR, Perez-Jeldres T, et al\nInflamm Bowel Dis. 2020;26:216-228.\nWANG X, Bootsma H, Kroese F, Dijkstra G, et al\nSenescent Stem and Transient Amplifying Cells in Crohn's Disease Intestine.\nInflamm Bowel Dis. 2020;26:e8-e9.\nLEWIS JD, Rutgeerts P, Feagan BG, D'haens G, et al\nInflamm Bowel Dis. 2020;26:304-313.\nEGBERG MD, Galanko JA, Kappelman MD\nInflamm Bowel Dis. 2020;26:254-260.\nLAURETI S, Gionchetti P, Cappelli A, Vittori L, et al\nRefractory Complex Crohn's Perianal Fistulas: A Role for Autologous Microfragmented Adipose Tissue Injection.\nInflamm Bowel Dis. 2020;26:321-330.\nMORAES L, Magnusson MK, Mavroudis G, Polster A, et al\nSystemic Inflammatory Protein Profiles Distinguish Irritable Bowel Syndrome (IBS) and Ulcerative Colitis, Irrespective of Inflammation or IBS-Like Symptoms.\nInflamm Bowel Dis. 2020 Jan 4. pii: 5696669. doi: 10.1093.\nInflamm Bowel Dis. 2020 Jan 2. pii: 5694104. doi: 10.1093.\nKUROWSKI JA, Achkar JP\nUnderutilization of Combination Anti-TNF Therapy in Population-based Study.\nInflamm Bowel Dis. 2020;26:158-159.\nDE FELICE KM\nPatients Perception of Risks and Benefits of Biologic Therapy.\nInflamm Bowel Dis. 2020;26:147-149.\nFRANCO DL, Click B\nProactive Versus Reactive Therapeutic Drug Monitoring of Infliximab in Crohn's Disease: Is the Juice Worth the Squeeze?\nInflamm Bowel Dis. 2020;26:112-113.\nSILVA JC, Rodrigues A, Carvalho J\nInflamm Bowel Dis. 2020;26:e1-e2.\nCHIBA M, Tsuji T, Nakane K, Obara Y, et al\nSwift Efficacy with Infliximab 4 Years after Initial Standard Induction Therapy Followed by Severe Delayed Infusion Reaction in Crohn's Disease.\nInflamm Bowel Dis. 2020;26:e4.\nSHANKAR U, Vijayasekar K, Bansal R, Walfish A, et al\nTreatment of Rituximab-induced Crohn's Disease With Ustekinumab Induction and Long-term Maintenance of Remission.\nInflamm Bowel Dis. 2020;26:e3.\nFAHAD H, Abu-Elmagd K, Lashner B, Fiocchi C, et al\nRecurrence of Crohn's Disease After Small Bowel Transplantation: Fact or Fiction.\nInflamm Bowel Dis. 2020;26:21-23.\nYU Y, Yang W, Li Y, Cong Y, et al\nEnteroendocrine Cells: Sensing Gut Microbiota and Regulating Inflammatory Bowel Diseases.\nInflamm Bowel Dis. 2020;26:11-20.\nWILSON R, Gundamaraju R, Vemuri R, Angelucci C, et al\nIdentification of Key Pro-Survival Proteins in Isolated Colonic Goblet Cells of Winnie, a Murine Model of Spontaneous Colitis.\nInflamm Bowel Dis. 2020;26:80-92.\nELIAS ED, Targownik LE, Singh H, Bernstein CN, et al\nInflamm Bowel Dis. 2020;26:150-157.\nKOLIANI-PACE JL, Haron AM, Zisman-Ilani Y, Thompson KD, et al\nPatients' Perceive Biologics to Be Riskier and More Dreadful Than Other IBD Medications.\nInflamm Bowel Dis. 2020;26:141-146.\nSTOLZER I, Kaden-Volynets V, Ruder B, Letizia M, et al\nInflamm Bowel Dis. 2020;26:66-79.\nCHRISTIAN KE, Russman KM, Rajan DP, Barr EA, et al\nInflamm Bowel Dis. 2020;26:125-131.\nWINTER RW, Friedman S\nUnderstanding the Cause of Weight Gain in Patients With IBD on Anti-TNF Medications.\nInflamm Bowel Dis. 2020;26:132-133.\nNEGOESCU DM, Enns EA, Swanhorst B, Baumgartner B, et al\nInflamm Bowel Dis. 2020;26:103-111.\nPASHA SF, Pennazio M, Rondonotti E, Wolf D, et al\nInflamm Bowel Dis. 2020;26:33-42.\nDAI C, Jiang M, Sun MJ\nDisease Duration and the Risk of Treatment Failure in Biologic-Treated Patients with Ulcerative Colitis.\nInflamm Bowel Dis. 2019 Dec 30. pii: 5690100. doi: 10.1093.\nKEVANS D, Kirsch R, Dargavel C, Kabakchiev B, et al\nHistological Markers of Clinical Relapse in Endoscopically Quiescent Ulcerative Colitis.\nInflamm Bowel Dis. 2019 Dec 28. pii: 5688912. doi: 10.1093.\nESCUDERO-HERNANDEZ C, Montalvillo E, Antolin B, Bernardo D, et al\nInflamm Bowel Dis. 2019 Dec 28. pii: 5688873. doi: 10.1093.\nFAYE AS, Oh A, Kumble LD, Kiran RP, et al\nFertility Impact of Initial Operation Type for Female Ulcerative Colitis Patients.\nInflamm Bowel Dis. 2019 Dec 27. pii: 5688242. doi: 10.1093.\nKUENZIG ME, Hawken S, Wilson K, Talarico R, et al\nInflamm Bowel Dis. 2019 Dec 12. pii: 5674034. doi: 10.1093.\nIntestinal Microbiota Transplantation for Patients With Inflammatory Bowel Disease Prevents Recurrence of C. difficile Infections but Not Recurrence of Gastrointestinal Symptoms.\nInflamm Bowel Dis. 2019 Dec 10. pii: 5673070. doi: 10.1093.\nTARIQ R, Disbrow MB, Dibaise JK, Orenstein R, et al\nInflamm Bowel Dis. 2019 Dec 9. pii: 5673067. doi: 10.1093.\nPOUILLON L, Hoefkens E, Verheyen V, Bronswijk M, et al\nLetter to the Editor: Feasibility and Efficiency of an E-Health Preadmission Assessment System for Intravenous Therapy in Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2019 Dec 3. pii: 5650900. doi: 10.1093.\nYANG B, Liu X, Mei Q\nInflamm Bowel Dis. 2019 Dec 3. pii: 5650909. doi: 10.1093.\nInflamm Bowel Dis. 2019 Dec 3. pii: 5650796. doi: 10.1093.\nOUAHED J, Spencer E, Kotlarz D, Shouval DS, et al\nInflamm Bowel Dis. 2019 Dec 3. pii: 5675340. doi: 10.1093.\nCHENG J, Shen H, Chowdhury R, Abdi T, et al\nPotential of Electrical Neuromodulation for Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2019 Nov 29. pii: 5648005. doi: 10.1093.\nJODELEIT H, Caesar J, Villarroel Aguilera C, Sterz S, et al\nThe Combination of Patient Profiling and Preclinical Studies in a Mouse Model Based on NOD/Scid IL2Rgamma null Mice Reconstituted With Peripheral Blood Mononuclear Cells From Patients With Ulcerative Colitis May Lead to Stratification of Patients for\nInflamm Bowel Dis. 2019 Nov 29. pii: 5648003. doi: 10.1093.\nCHATEAU T, Peyrin-Biroulet L\nTwo Cases of Inflammatory Bowel Disease Patients Treated With Ustekinumab 90 mg Every 3 Weeks.\nInflamm Bowel Dis. 2019 Nov 26. pii: 5643743. doi: 10.1093.\nCHANDRAKUMAR A, Zohni H, El-Matary W\nInflamm Bowel Dis. 2019 Nov 25. pii: 5643019. doi: 10.1093.\nBASSON AR, Gomez-Nguyen A, Menghini P, Butto LF, et al\nInflamm Bowel Dis. 2019 Nov 21. pii: 5637456. doi: 10.1093.\nNGUYEN NH, Kurnool S, Dulai PS, Boland BS, et al\nInflamm Bowel Dis. 2019 Nov 21. pii: 5636894. doi: 10.1093.\nMARCIL V, Levy E, Amre D, Bitton A, et al\nInflamm Bowel Dis. 2019 Nov 20. pii: 5634260. doi: 10.1093.\nTHAKUR ER, Sansgiry S, Kramer JR, Waljee AK, et al\nInflamm Bowel Dis. 2019 Nov 15. pii: 5625871. doi: 10.1093.\nHANSEN TM, Sabourin BC, Oketola B, Bernstein CN, et al\nInflamm Bowel Dis. 2019 Nov 14. pii: 5625670. doi: 10.1093.\nSHMIDT E, Saha S, Sands BE\nInflamm Bowel Dis. 2019;25:e166.\nFAYE AS, Hung KW, Cheng K, Blackett JW, et al\nInflamm Bowel Dis. 2019 Nov 5. pii: 5613524. doi: 10.1093.\nMARTINELLI M, Giugliano FP, Strisciuglio C, Urbonas V, et al\nInflamm Bowel Dis. 2019 Nov 5. pii: 5613525. doi: 10.1093.\nLOPETUSO LR, Gasbarrini A\nInflamm Bowel Dis. 2019 Nov 5. pii: 5613523. doi: 10.1093.\nVADSTRUP K, Alulis S, Borsi A, Gustafsson N, et al\nCost Burden of Crohn's Disease and Ulcerative Colitis in the 10-Year Period Before Diagnosis-A Danish Register-Based Study From 2003-2015.\nInflamm Bowel Dis. 2019 Nov 4. pii: 5613986. doi: 10.1093.\nDE JONG ME, Gillis VELM, Derikx LAAP, Hoentjen F, et al\nInflamm Bowel Dis. 2019 Nov 2. pii: 5611176. doi: 10.1093.\nSHAH NB, Haydek J, Slaughter J, Ashton JR, et al\nInflamm Bowel Dis. 2019 Oct 31. pii: 5610710. doi: 10.1093.\nCLICK B, Lopez R, Arrigain S, Schold J, et al\nShifting Cost-drivers of Health Care Expenditures in Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2019 Oct 31. pii: 5610752. doi: 10.1093.\nTRUTA B, Leeds IL, Canner JK, Efron JE, et al\nInflamm Bowel Dis. 2019 Oct 31. pii: 5610578. doi: 10.1093.\nGU P, Feagins LA\nDining With Inflammatory Bowel Disease: A Review of the Literature on Diet in the Pathogenesis and Management of IBD.\nInflamm Bowel Dis. 2019 Oct 31. pii: 5610412. doi: 10.1093.\nAL DRAIWEESH S, Ma C, Alkhattabi M, McDonald C, et al\nInflamm Bowel Dis. 2019 Oct 28. pii: 5608313. doi: 10.1093.\nMCCOMBIE A, Walmsley R, Barclay M, Ho C, et al\nA Noninferiority Randomized Clinical Trial of the Use of the Smartphone-Based Health Applications IBDsmart and IBDoc in the Care of Inflammatory Bowel Disease Patients.\nInflamm Bowel Dis. 2019 Oct 23. pii: 5603780. doi: 10.1093.\nCALVET X, Saldana R, Carpio D, Minguez M, et al\nImproving Quality of Care in Inflammatory Bowel Disease Through Patients' Eyes: IQCARO Project.\nInflamm Bowel Dis. 2019 Oct 21. pii: 5571234. doi: 10.1093.\nBARNES EL, Jiang Y, Kappelman MD, Long MD, et al\nInflamm Bowel Dis. 2019 Oct 21. pii: 5601649. doi: 10.1093.\nHAAC BE, Nemirovsky A, Teeter W, Geyer A, et al\nInjury Characteristics and Outcomes of Patients With Inflammatory Bowel Disease After Trauma: A Propensity Score Matched Analysis.\nInflamm Bowel Dis. 2019 Oct 21. pii: 5601417. doi: 10.1093.\nGROSSI V, Hyams JS, Glidden NC, Knight BE, et al\nInflamm Bowel Dis. 2019 Oct 18. pii: 5599699. doi: 10.1093.\nKRISTENSEN MS, Kjaerulff TM, Ersboll AK, Green A, et al\nErratum: The Influence of Antidepressants on the Disease Course Among Patients With Crohn's Disease and Ulcerative Colitis-A Danish Nationwide Register-Based Cohort Study.\nInflamm Bowel Dis. 2019;25:e152.\nWANG MH, Mousa OY, Friton JJ, Raffals LE, et al\nUnique Phenotypic Characteristics and Clinical Course in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis: A Multicenter US Experience.\nInflamm Bowel Dis. 2019 Oct 18. pii: 5593848. doi: 10.1093.\nVAN DER HAVE M, Oldenburg B\nInflamm Bowel Dis. 2019 Oct 18. pii: 5598454. doi: 10.1093.\nSINGH A, Koenen B, Kirby DF\nInflamm Bowel Dis. 2019 Oct 18. pii: 5598917. doi: 10.1093.\nContraception and Antibiotics.\nInflamm Bowel Dis. 2019;25:e148.\nMIRJALALI H, Shahrokh S, Asadzadeh Aghdaei H, Zali MR, et al\nLetter to the Editor: Activated Toxoplasma May Attenuate the Effect of Azathioprine and Deteriorate the Symptoms in IBD Patients via mTORC1 Manipulation.\nInflamm Bowel Dis. 2019;25:e137.\nEISENSTEIN S, Holubar SD, Hilbert N, Bordeianou L, et al\nThe ACS National Surgical Quality Improvement Program-Inflammatory Bowel Disease Collaborative: Design, Implementation, and Validation of a Disease-specific Module.\nInflamm Bowel Dis. 2019 Oct 17. pii: 5589173. doi: 10.1093.\nLAI SW, Kuo YH, Fang CW, Liao KF, et al\nInflammatory Bowel Disease and the Risk of Erectile Dysfunction.\nInflamm Bowel Dis. 2019 Oct 17. pii: 5589171. doi: 10.1093.\nRecommendations for the Provision of Psychological Support in a Rural Inflammatory Bowel Disease Clinic.\nInflamm Bowel Dis. 2019 Oct 17. pii: 5589169. doi: 10.1093.\nNETO MBB, Gregory MH, Ramos GP, Bazerbachi F, et al\nInflamm Bowel Dis. 2019 Oct 15. pii: 5588067. doi: 10.1093.\nKAFIL TS, Nguyen TM, MacDonald JK, Chande N, et al\nCannabis for the Treatment of Crohn's Disease and Ulcerative Colitis: Evidence From Cochrane Reviews.\nInflamm Bowel Dis. 2019 Oct 15. pii: 5588062. doi: 10.1093.\nLAI SW, Kuo YH, Liao KF\nCancer Risk in Inflammatory Bowel Disease.\nInflamm Bowel Dis. 2019 Oct 14. pii: 5587055. doi: 10.1093.\nSCHOFIELD JB, Haboubi N\nInflamm Bowel Dis. 2019 Oct 10. pii: 5584939. doi: 10.1093.\nKRISHNA M, Salako A, Fofanova T, Kellermayer R, et al\nParental Education May Differentially Impact Pediatric Inflammatory Bowel Disease Phenotype Risk.\nInflamm Bowel Dis. 2019 Oct 6. pii: 5581966. doi: 10.1093.\nRe: Parental Education May Differentially Modulate Pediatric Inflammatory Bowel Disease Phenotype Risk.\nInflamm Bowel Dis. 2019 Oct 6. pii: 5581964. doi: 10.1093.\nNARDONE OM, Shivaji UN, Ferruzza V, Ghosh S, et al\nSoluble Blood Markers of Mucosal Healing in Inflammatory Bowel Disease: The Future of Noninvasive Monitoring.\nInflamm Bowel Dis. 2019 Oct 6. pii: 5581902. doi: 10.1093.\nKAYAL M, Plietz M, Rizvi A, Radcliffe M, et al\nInflamm Bowel Dis. 2019 Oct 6. pii: 5581903. doi: 10.1093.\nDANILUK U, Daniluk J, Ciborowski M\nReply to Letter to the Editor of Dr. Sitkin et al., Regarding "Altered Sphingolipid Metabolism and its Interaction With the Intestinal Microbiome is Another Key to the Pathogenesis of Inflammatory Bowel Disease".\nInflamm Bowel Dis. 2019 Sep 27. pii: 5574842. doi: 10.1093.\nSITKIN S, Demyanova E, Vakhitov T, Pokrotnieks J, et al\nInflamm Bowel Dis. 2019 Sep 27. pii: 5574840. doi: 10.1093.\nCHANDE N, Costello SP, Limketkai BN, Parker CE, et al\nInflamm Bowel Dis. 2019 Sep 27. pii: 5574841. doi: 10.1093.\nMOSER T, Bubel NE, Machegger L, Pikija S, et al\nCerebral Vasculitis in Crohn's Disease: Always a Complication of Inflammatory Bowel Disease or Tumor Necrosis Factor-Alpha Inhibition?\nInflamm Bowel Dis. 2019 Sep 27. pii: 5574838. doi: 10.1093.\nKELSEN JR, Conrad MA, Dawany N, Patel T, et al\nInflamm Bowel Dis. 2019 Sep 27. pii: 5575070. doi: 10.1093.\nGIRON F, Pasto A, Tasciotti E, Abraham BP, et al\nInflamm Bowel Dis. 2019 Sep 27. pii: 5574918. doi: 10.1093.\nLONG MD, Smith TW, Dibonaventura M, Gruben D, et al\nInflamm Bowel Dis. 2019 Sep 27. pii: 5574848. doi: 10.1093.\nABU-SBEIH H, Wang Y\nInflamm Bowel Dis. 2019 Sep 27. pii: 5574910. doi: 10.1093.\nNGUYEN GC, Low D, Chong RY, Diong C, et al\nUtilization of Diagnostic Imaging and Ionization Radiation Exposure Among an Inflammatory Bowel Disease Inception Cohort.\nInflamm Bowel Dis. 2019 Sep 27. pii: 5574895. doi: 10.1093.\nCHIBA M, Nakane K, Abe H, Komatsu M, et al\nInflamm Bowel Dis. 2019 Sep 27. pii: 5574851. doi: 10.1093.\nCLARKE WT, Papamichael K, Casteele NV, Germansky KA, et al\nInflamm Bowel Dis. 2019 Sep 27. pii: 5574728. doi: 10.1093.\nVAN DE VEN SEM, Derikx LAAP, Nagtegaal ID, van Herpen CM, et al\nInflamm Bowel Dis. 2019 Sep 27. pii: 5574717. doi: 10.1093.\nBOLAND K, Greener T, Kabakchiev B, Stempak J, et al\nInflamm Bowel Dis. 2019 Sep 17. pii: 5570706. doi: 10.1093.\nLUTHER J, Dave M\nRising Inflammatory Bowel Disease Prevalence Highlights the Need for Effective, Cost-Effective Therapies.\nInflamm Bowel Dis. 2019 Sep 7. pii: 5565004. doi: 10.1093.\nResponse to the Letter by Dr. Freddy Calder.\nInflamm Bowel Dis. 2019;25:e104.\nBORUM ML, Taneja SL, Corinaldi M\nHealth Literacy Assessments May Be Inconsistently Conducted in IBD Patients.\nInflamm Bowel Dis. 2019;25:e94.\nSAROLI PALUMBO C, Bessissow T, Sebastiani G\nReply to "Transient Elastography in IBD Patients".\nInflamm Bowel Dis. 2019;25:e95.\nVAN EVERDINGEN CK, Meijer B, Gearry RB\nTransient Elastography in IBD Patients.\nInflamm Bowel Dis. 2019;25:e96.\nGOYAL A, Morowitz M\nAuthor's Reply to Drs. Franco Scaldaferri and Valentina Petito, PhD.\nInflamm Bowel Dis. 2019;25:e102.\nKOCHAR B, Long MD, Herfarth HH\nInflamm Bowel Dis. 2019;25:e98.\nNARULA N, Pinto-Sanchez MI, Calo NC, Ford AC, et al\nInflamm Bowel Dis. 2019;25:e99.\nZHAO S, Xie Q, Zhao Z\nInflamm Bowel Dis. 2019;25:e78-e81.\nReproducibility and Transportability of the Absence of Incremental Infectious Adverse Events in Patients With Higher Anti-TNF Drug Levels.\nInflamm Bowel Dis. 2019;25:e73.\nKRUGER AJ, Hinton A, Afzali A\nTo the Editors: Index Severity Score and Early Readmission Predicts Increased Mortality in Crohn's Disease Patients.\nInflamm Bowel Dis. 2019;25:e74-e76.\nKURIN M, Katz J, Kodish E, Lashner B, et al\nInflamm Bowel Dis. 2019;25:1115-1119.\nInflamm Bowel Dis. 2019;25:e84.\nGARCIA GARCIA MJ, Rivero Tirado M, Callizo MEP\nParadoxical Arthritis in Inflammatory Bowel Diasease Patients on Ustekinumab Treatment.\nInflamm Bowel Dis. 2019;25:e89.\nSIMONS-LINARES CR, Chahal P\nSuccessful EUS-guided Drainage of a Persistent Subdiaphragmatic Fluid Collection in a Patient With Crohn's Disease.\nInflamm Bowel Dis. 2019;25:e85-e86.\nLIGHTNER AL, Alsughayer A, Wang Z, McKenna NP, et al\nInflamm Bowel Dis. 2019;25:1152-1168.\nKRISHNAKUMAR C, Ballengee CR, Liu C, Kim MO, et al\nInflamm Bowel Dis. 2019;25:1208-1217.\nZHAO M, Lo BZS, Vester-Andersen MK, Vind I, et al\nA 10-Year Follow-up Study of the Natural History of Perianal Crohn's Disease in a Danish Population-Based Inception Cohort.\nInflamm Bowel Dis. 2019;25:1227-1236.\nEVERHOV AH, Khalili H, Askling J, Myrelid P, et al\nWork Loss Before and After Diagnosis of Crohn's Disease.\nInflamm Bowel Dis. 2019;25:1237-1247.\nDELDAY M, Mulder I, Logan ET, Grant G, et al\nInflamm Bowel Dis. 2019;25:e72.\nFUKUDA T, Naganuma M, Kanai T\nInflamm Bowel Dis. 2019;25:e68.\nBRYANT RV, Schultz CG, Ooi S, Goess C, et al\nInflamm Bowel Dis. 2019;25:e62-e63.\nInflamm Bowel Dis. 2019;25:e61.\nGREENFEST A, Szvarca D, Clarke L, Tabbara N, et al\nNew Vaccine, New Guidelines, Same Problem: The Rates of Herpes Zoster Infection and Vaccination in IBD Patients.\nInflamm Bowel Dis. 2019;25:e60.\nCOUCH DG, Cook H, Ortori C, Barrett D, et al\nInflamm Bowel Dis. 2019;25:1006-1018.\nCALDERA F, Hayney MS, Cross RK\nUsing Number Needed to Harm to Put the Risk of Herpes Zoster From Tofacitinib in Perspective.\nInflamm Bowel Dis. 2019;25:955-957.\nMOORE AC, Huang VW, Bourdages R, Fedorak RN, et al\nInflamm Bowel Dis. 2019;25:1107-1114.\nKOTZEV A, Tanchev L, Encheva L, Kovachev N, et al\nSigmoidouterine Fistula in Crohn's Disease: A First Case Report.\nInflamm Bowel Dis. 2019;25:e65-e66.\nQAZI T, Verma R, Hamilton MJ, Kaplan ER, et al\nInflamm Bowel Dis. 2019;25:1044-1053.\nSADO AI, Kalla R, Sharma A\nA Case of IBD Immunosuppression Related Salmonella Aortitis Requiring Emergency Vascular Grafting.\nInflamm Bowel Dis. 2019;25:e64.\nSCHMIDT T, Feagins LA\nInflamm Bowel Dis. 2019;25:980-986.\nPARK SH, Aniwan S, Scott Harmsen W, Tremaine WJ, et al\nInflamm Bowel Dis. 2019;25:1054-1060.\nPLEVRIS N, Lyons M, Jenkinson PW, Chuah CS, et al\nInflamm Bowel Dis. 2019;25:1036-1043.\nSHMIDT E, Dulai PS\nReply to the Letter to the Editor of Dr. Pauwels et al.\nInflamm Bowel Dis. 2019;25:e58.\nEthnicity May Be Important for Studying the Role of the Microbiome and Vitamin D Receptor in IBD.\nInflamm Bowel Dis. 2019;25:e54.\nSZYMCZAK-TOMCZAK A, Krela-Kazmierczak I, Kaczmarek-Rys M, Hryhorowicz S, et al\nDoes Only Sex Matter? Complexity of the Association Between Vdr Gene BsmI Single Nucleotide Polymorphism and Immune Response in IBD.\nInflamm Bowel Dis. 2019;25:e56-e57.\nCHETCUTI ZAMMIT S, McAlindon ME, Hale MF, Sanders DS, et al\nSmall Bowel Ulcers on Capsule Endoscopy and Their Significance.\nInflamm Bowel Dis. 2019;25:e55.\nInflamm Bowel Dis. 2019;25:e52.\nFRANCO DL, Holubar SD, Lightner AL, Lashner BA, et al\nLocal Stem Cell Therapy for Crohn's Perianal Fistulae.\nInflamm Bowel Dis. 2019;25:816-819.\nSCOTT FI, Johnson FR, Bewtra M, Brensinger CM, et al\nInflamm Bowel Dis. 2019;25:925-936.\nCHUDY-ONWUGAJE KO, Christian KE, Farraye FA, Cross RK, et al\nA State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD.\nInflamm Bowel Dis. 2019;25:820-830.\nCLICK B, Regueiro M\nA Practical Guide to the Safety and Monitoring of New IBD Therapies.\nInflamm Bowel Dis. 2019;25:831-842.\nNUCERA E, Andriollo G, Buonomo A, Di Rienzo A, et al\nInflamm Bowel Dis. 2019;25:e49-e51.\nGOREN I, Godny L, Reshef L, Yanai H, et al\nStarch Consumption May Modify Antiglycan Antibodies and Fecal Fungal Composition in Patients With Ileo-Anal Pouch.\nInflamm Bowel Dis. 2019;25:742-749.\nZHAO S, Wang J, Liu Y, Luo L, et al\nInflamm Bowel Dis. 2019;25:699-707.\nWEAVER KN, Gregory M, Syal G, Hoversten P, et al\nInflamm Bowel Dis. 2019;25:767-774.\nDURICOVA D, Dvorakova E, Hradsky O, Mitrova K, et al\nInflamm Bowel Dis. 2019;25:789-796.\nCARUSO ML, Cavalcanti E, Ignazzi A, Lantone G, et al\nInfliximab Has a Number of Well-Described Adverse Effects. Is Myeloid Metaplasia One of These in Elderly Long-standing IBD Patients?\nInflamm Bowel Dis. 2019;25:e44-e45.\nMAO R, Kurada S, Gordon IO, Baker ME, et al\nThe Mesenteric Fat and Intestinal Muscle Interface: Creeping Fat Influencing Stricture Formation in Crohn's Disease.\nInflamm Bowel Dis. 2019;25:421-426.\nVisceral Adipose Tissue Is Associated With Stricturing Crohn's Disease Behavior, Fecal Calprotectin, and Quality of Life.\nInflamm Bowel Dis. 2019;25:592-600.\nARMUZZI A, Fiorino G, Variola A, Manetti N, et al\nInflamm Bowel Dis. 2019;25:568-579.\nDENSON LA, Jurickova I, Karns R, Shaw KA, et al\nInflamm Bowel Dis. 2019;25:547-560.\nQUINN KP, Lightner AL, Faubion WA, Raffals LE, et al\nInflamm Bowel Dis. 2019;25:460-471.\nNUGENT Z, Singh H, Targownik LE, Bernstein CN, et al\nHerpes Zoster Infection and Herpes Zoster Vaccination in a Population-Based Sample of Persons With IBD: Is There Still an Unmet Need?\nInflamm Bowel Dis. 2019;25:532-540.\nMIZUNO S, Naganuma M, Kanai T\nIdiopathic Thrombocytopenic Purpura Responsive to Surgery for Crohn's Disease.\nInflamm Bowel Dis. 2019;25:e26.\nNOVELLO M, Shen B, Stocchi L\nPouchitis as an Indication for Ileal Pouch Surgical Revision.\nInflamm Bowel Dis. 2019;25:e25.\nGLAPA A, Waraczewski K, Nowak JK, Paszkowski J, et al\nVitamin K Deficiency in Patients After Restorative Proctocolectomy.\nInflamm Bowel Dis. 2019;25:e17-e18.\nEL OUALI S, Kessler H, Shen B\nSelf-Expandable Metal Stent in the Treatment of Refractory Long Pouch Inlet Stricture.\nInflamm Bowel Dis. 2019;25:e13-e14.\nDOVROLIS N, Drygiannakis I, Filidou E, Kandilogiannakis L, et al\nGut Microbial Signatures Underline Complicated Crohn's Disease but Vary Between Cohorts; An In Silico Approach.\nInflamm Bowel Dis. 2019;25:217-225.\nWEIZMAN AV, Nguyen GC, Seow CH, Targownik L, et al\nInflamm Bowel Dis. 2019;25:328-335.\nSHEN W, Li Y, Zou Y, Cao L, et al\nInflamm Bowel Dis. 2019;25:283-293.\nSCHIRBEL A, Rebert N, Sadler T, West G, et al\nInflamm Bowel Dis. 2019;25:294-305.\nBEN-SHACHAR S, Finezilber Y, Elad H, Rabinowitz K, et al\nInflamm Bowel Dis. 2019;25:336-344.\nBITTON A, Vutcovici M, Lytvyak E, Kachan N, et al\nInflamm Bowel Dis. 2019;25:403-409.\nDURICOVA D, Sarter H, Savoye G, Leroyer A, et al\nInflamm Bowel Dis. 2019;25:394-402.\nXU Y, Yang L, An P, Zhou B, et al\nMeta-Analysis: The Influence of Preoperative Infliximab Use on Postoperative Complications of Crohn's Disease.\nInflamm Bowel Dis. 2019;25:261-269.\nDEEPAK P, Fowler KJ, Fletcher JG, Bruining DH, et al\nInflamm Bowel Dis. 2019;25:248-260.\nSHAFER LA, Walker JR, Restall G, Chhibba T, et al\nInflamm Bowel Dis. 2019;25:352-359.\nRIVERA ED, Coffey JC, Walsh D, Ehrenpreis ED, et al\nThe Mesentery, Systemic Inflammation, and Crohn's Disease.\nInflamm Bowel Dis. 2019;25:226-234.\nRENOUF MJ, Cho YH, McPhee JB\nInflamm Bowel Dis. 2019;25:33-44.\nBUTTO LF, Jia LG, Arseneau KO, Tamagawa H, et al\nInflamm Bowel Dis. 2019;25:14-26.\nZHANG YG, Lu R, Xia Y, Zhou D, et al\nLack of Vitamin D Receptor Leads to Hyperfunction of Claudin-2 in Intestinal Inflammatory Responses.\nInflamm Bowel Dis. 2019;25:97-110.\nInflamm Bowel Dis. 2019;25:85-96.\nSTEINHART AH, Panaccione R, Targownik L, Bressler B, et al\nInflamm Bowel Dis. 2019;25:1-13.\nCUSHING KC, Mclean R, McDonald KG, Gustafsson JK, et al\nPredicting Risk of Postoperative Disease Recurrence in Crohn's Disease: Patients With Indolent Crohn's Disease Have Distinct Whole Transcriptome Profiles at the Time of First Surgery.\nInflamm Bowel Dis. 2019;25:180-193.\nSPENCER E, Norris E, Williams C, Dubinsky MC, et al\nThe Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBD.\nInflamm Bowel Dis. 2019;25:142-149.\nEL-MATARY W, Walters TD, Huynh HQ, deBruyn J, et al\nInflamm Bowel Dis. 2019;25:150-155.\nSAROLI PALUMBO C, Restellini S, Chao CY, Aruljothy A, et al\nInflamm Bowel Dis. 2019;25:124-133.\nLEGA S, Phan BL, Rosenthal CJ, Gordon J, et al\nProactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD.\nInflamm Bowel Dis. 2019;25:134-141.\nDOTSON JL, Kappelman MD, Bricker J, Andridge R, et al\nInflamm Bowel Dis. 2019;25:194-203.